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Abstract 
The human immunodeficiency virus (HIV) is a lentivirus responsible for HIV infection and acquired 
immunodeficiency syndrome (AIDS). This virus uses the central nervous system (CNS) as reservoir, 
especially the brain, which turns it as a promising target to fight this pathology. The antiretroviral 
efavirenz (EFV), applied in the HIV therapy, is usually not able to reach the CNS due to the difficulties in 
surpass the blood-brain barrier (BBB). Nanoparticles (NPs) hold tremendous potential in overcome the 
BBB, demonstrating to be an effective drug delivery system to the CNS. Since the conventional bulk 
approaches to produce NPs lack a precise control over the final properties of the nanosystems, 
microfluidic platforms emerged as a prospective solution to circumvent this drawback, providing much 
more uniform and tunable formulations.  
In this work, a formulation of EFV-loaded poly(lactic-co-glycolic acid) (PLGA) NPs was produced 
through an innovative microfluidic platform, using the nanoprecipitation technique. In comparison with 
the conventionally-performed nanoprecipitation, the nanoformulation obtained through the microfluidic 
platform resulted in reduced NPs average size (133.0 nm for the conventional method; 72.8 nm for 
microfluidics), comparable NPs polydispersity index (0.090 for the conventional method; 0.086 for 
microfluidics), and less negative surface charge (-28.0 mV for the conventional method; -14.1 mV for 
microfluidics). This decrease in size is an advantageous feature for brain-targeted drug delivery. With 
microfluidics, higher EFV association efficiency (32.7 % for the conventional method; 80.7 % for 
microfluidics) and drug loading (3.2 % for the conventional method; 10.8 % for microfluidics) were 
obtained. The robustness of the microfluidic method was successfully demonstrated by a scaling 
experiment, which proved that physico-chemical properties of NPs were not affected by changes in the 
final volume of batches. The microfluidics-associated EFV-loaded nanosystem also demonstrated to be 
constituted by homogeneous round-shaped particles, containing a residual amount of the organic solvent 
used in the production methodology and with a sustained in vitro drug release profile over time from 
their matrix. The EFV-loaded NPs proved to be safe to BBB endothelial cells (hCMEC/D3 cell line) and 
brain parenchyma neuron cells (ND7/23 cell line), providing protection compared to the free drug. 
Hemolysis studies demonstrated a nonhemolytic behavior of the NPs, which presented only approximately 
1-2 % of hemolysis and did not cause morphological changes in red blood cells. The microfluidics-
associated EFV-loaded PLGA NPs were further functionalized with a transferrin receptor-binding 12-amino 
acids peptide, using the carbodiimide chemistry. Herein, Bradford test and nuclear magnetic resonance 
analysis suggested an effective surface functionalization of NPs. Finally, functionalized NPs were able to 
interact with BBB endothelial cells, and EFV permeated through a BBB in vitro model. Therefore, the 
work developed in the scope of this dissertation confirmed the advantages of microfluidics over 
conventional methodologies in the loading of the anti-HIV drug EFV in PLGA NPs, which presented 
suitable properties to be possibly administered by the intravenous route, in order to target the BBB.  
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Resumo 
O vírus da imunodeficiência humana (VIH) é um lentivírus que está na origem de uma infeção viral e 
da síndrome da imunodeficiência adquirida (SIDA). O Sistema Nervoso Central (SNC) é um reservatório 
viral do VIH por excelência, principalmente o cérebro, o que o torna num alvo promissor para o combate 
desta patologia. O antirretroviral efavirenz (EFV), usado na terapia do VIH, apresenta geralmente uma 
capacidade reduzida de atingir o SNC devido à dificuldade em ultrapassar a barreira hematoencefálica 
(BHE). As nanopartículas (NPs) têm um elevado potencial nesta área, demonstrando ser capazes de 
ultrapassar a BHE e eficazes sistemas de entrega de fármacos para o SNC. Dado que as metodologias de 
produção de NPs baseadas em metodologias convencionais estão ligadas à carência de um controlo exato 
sobre as propriedades finais dos nanossistemas, as plataformas associadas à tecnologia de microfluídos 
surgem assim como uma possível solução para contornar esta problemática, providenciando formulações 
mais uniformes e versáteis.  
Neste trabalho, uma formulação de NPs de ácido poli(láctico-co-glicólico) (PLGA) carregadas com EFV 
foi produzida por uma inovadora plataforma associada à tecnologia de microfluídos, com recurso à 
técnica de nanoprecipitação. Por comparação com a nanoprecipitação executada por metodologia 
convencional, a nanoformulação obtida pela execução da mesma técnica num ambiente microfluídico 
apresentou um tamanho médio inferior (133.0 nm para o método convencional; 72.8 nm para a 
tecnologia de microfluídos), uma comparável polidispersão das NPs (0.090 para o método convencional; 
0.086 para a tecnologia de microfluídos) e uma carga superficial menos negativa (-28.0 mV para o 
método convencional; -14.1 mV para a tecnologia de microfluídos). A diminuição do tamanho médio das 
NPs é uma característica vantajosa no que diz respeito à entrega de fármacos direcionada para o 
cérebro. A tecnologia de microfluídos permitiu obter resultados melhores relativamente à eficiência de 
associação do fármaco (32.7 % para o método convencional; 80.7 % para a tecnologia de microfluídos) e 
dosagem do mesmo (3.2 % para o método convencional; 10.8 % para a tecnologia de microfluídos) nas 
NPs. A robustez do método implementado para a produção de NPs a partir da tecnologia de microfluídos 
foi comprovada com sucesso através de uma experiência de “scaling”, que provou que as propriedades 
físico-químicas das NPs não são afetadas pela alteração do volume final da formulação. O nanossistema 
carregado com EFV resultante da tecnologia de microfluídos também demonstrou ser constituído por 
partículas homogéneas e de forma arredondada, contendo apenas uma quantidade residual do solvente 
orgânico usado aquando da sua produção, e com uma libertação “in vitro” do fármaco controlada a 
partir da sua matriz, ao longo do tempo. Numa segunda fase, as NPs carregadas com EFV obtidas pela 
tecnologia de microfluídos demonstraram não apresentar citotoxicidade em células endoteliais da BHE 
(linha celular hCMEC/D3) nem em células neuronais do parênquima cerebral (linha celular ND7/23), 
providenciando proteção em comparação com o fármaco na sua forma livre. Os testes de hemólise 
evidenciaram o caráter não-hemolítico do nanossistema, sendo que este apresentou uma percentagem 
de hemólise de apenas cerca de 1-2 % sem causar alterações morfológicas em eritrócitos. De seguida, as 
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NPs de PLGA carregadas com EFV e produzidas pela tecnologia de microfluídos foram funcionalizadas 
através da química de carbodiimida com um péptido de 12 amino ácidos específico para ligação ao 
recetor da transferrina. O teste de Bradford e a análise de ressonância magnética nuclear foram 
efectuados e surgeriram a funcionalização superficial efetiva das NPs. Por fim, as NPs foram capazes de 
interagir com células endoteliais da BHE e o EFV permeou através de um modelo “in vitro” da BHE. 
Assim, o trabalho desenvolvido no âmbito desta dissertação confirmou as vantagens da tecnologia de 
microfluídos em relação às metodologias convencionais na incorporação do fármaco anti-VIH EFV em NPs 
de PLGA, que apresentaram propriedades adequadas para uma possível administração intravenosa, de 
forma a atingirem a BHE.  
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Chapter 1 
Introduction  
1.1 Context and motivation 
The central nervous system (CNS) is a well-protected structure by means of biological barriers, 
namely the blood-brain barrier (BBB). This barrier, which is mainly formed by endothelial cells that 
line cerebral microvessels, plays a key role in the maintenance of a precisely regulated CNS 
microenvironment [1]. However, the same mechanisms that protect this complex physiological 
system against dangerous compounds can also avoid brain-targeted drug delivery to be effective [2]. 
The conventional solutions offered to circumvent this problem are often associated with a 
neuroinvasive surgery [3]. 
Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) 
belong to a spectrum of conditions derived from the HIV. The HIV continues to be considered a 
major global public health issue since the virus attack specific types of immune cells, hence 
suppressing the immune system. Therefore, a lot of opportunistic infections or other diseases may 
appear and the body cannot act against them [4]. The HIV is characterized by a neurovirulent 
profile, thus being able to infect the brain, use the brain as reservoir, and cause severe CNS damage 
[5]. In consequence, the CNS is recognized as a sanctuary site for virus replication.  
The emergence of antiretroviral therapies (ARTs) against HIV resulted in virus-associated 
morbidity and mortality decline [5], allowing infected individuals to improve their life quality and 
expectancy. Efavirenz (EFV) is an antiretroviral (ARV) approved by Food and Drug Administration 
(FDA) for HIV infection treatment [6]. This drug attaches and blocks a virus-specific enzyme, the 
reverse transcriptase (RT) [7-9]. However, the importance of ARVs to penetrate the CNS continues 
to be debated. After the administration of a drug, its distribution throughout the body depends on 
its physico-chemical properties and molecular structure [10]. In the case of EFV and other ARVs, the 
final amount of drug that reaches CNS is only a small fraction of the administered dose. This means 
that, during the path, they interact with biological barriers and healthy tissues, which are not 
involved in the process, even causing the loss of the drug efficacy and the arrival of undesirable 
effects [11]. This drawback can be circumvented by formulating the drug into an appropriate drug 
delivery system (DDS) which is defined as a “formulation or a device that enables the introduction 
of a therapeutic substance in the body and improves its efficacy and safety by controlling the rate, 
time, and place of release of drugs in the body” [12]. Furthermore, to achieve an efficient 
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pharmacological activity of the drug at the site of action it is necessary to recognize some 
important aspects, such as the interactions of the components of these systems with the biological 
environment, the stability of therapeutic agents, and the molecular mechanisms of cell-signaling 
involved in the pathophysiology of the disease under consideration. Drug delivery systems are 
usually associated with small size, reduced toxicity and modification of drug pharmacokinetics [11, 
13]. 
Nanoparticles (NPs) are considered one of the most auspicious and versatile DDSs into regions of 
difficult access, like the brain, being able to provide protection to therapeutic agents while 
efficiently delivering them into the damaged areas [14]. For that reason, these novel approaches 
are able to face the challenge of crossing the protective barriers of the CNS [15], and also to 
prolong systemic drug circulation [16, 17].  Nanoparticles are considered a product of 
nanotechnology, which is the field of technology that aims to control, manipulate, study and 
engineer structures and devices in the “nanometer” size range [18]. The definition of nanomaterials 
may vary from the classical one, which considers any structure having at least one dimension value 
within the range 1-100 nm [19], to a more liberal interpretation, which considers any substance 
with particulate dimensions from 1 nm up to 999 nm. Considered the technology of the future by 
many, nanotechnology has applicability in a wide range of areas and is expected to open some new 
paths to fight and prevent diseases [20].  
Different materials are used to produce NPs, as polymers (polymeric NPs, micelles, dendrimers), 
lipids (liposomes), viruses (viral NPs), metals, or even organometallic compounds (nanotubes) [21, 
22]. Nowadays, polymeric NPs are most of the times preferred as DDSs due to their favorable 
properties for active pharmaceutical ingredients (APIs) loading and delivery. Particularly in this 
field, the biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) has shown immense potential 
[23]. 
There are several techniques to produce NPs as DDSs, which are suitable for several 
applications. Among them, nanoprecipitation may be used to encapsulate EFV in PLGA NPs. The 
successful loading of drugs within the NPs core depends mostly on APIs properties, NPs materials 
composition, and the encapsulation method [23]. Techniques performed by conventional bulk 
methods using equipments as homogenizers or magnetic stirrers and vassels offer several 
limitations, such as the lack of precise control of NPs properties. Regulatory institutions such as FDA 
and the European Commission pointed out that one of the major restrictions to the actual 
application of current nanotechnology is, in fact, the lack of homogeneous formulations of NPs [24]. 
Therefore, microfluidic platforms emerged as potential candidates to produce drug-loaded NPs in a 
well-controlled process using the same techniques. Microfluidics is associated with a fine 
manipulation of process parameters, thus providing the optimization of NPs properties, including 
encapsulation efficiency of drugs in the systems and monodispersity of batches. This method is able 
to tightly control the local particle-formation environment in a continuous flow pattern [25]. 
1.2 Objectives 
Herein, we aimed to develop a formulation of EFV-loaded PLGA NPs to target the CNS using the 
microfluidics technology. To the best of our knowledge, any microfluidic system to produce NPs 
with this polymeric matrix and to encapsulate this drug has been yet reported. Nanoprecipitation 
was the selected technique to perform drug encapsulation.  
The tasks planned in this dissertation were: 
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 Production of EFV-loaded NPs by the conventionally-performed technique (including a 
modified version of nanoprecipitation); 
 
 Production of EFV-loaded NPs by the technique performed through microfluidics using the 
co-flow and flow-focusing geometry of the fluids; 
 Comparison of NPs obtained by the two methodologies regarding particles physico-chemical 
characteristics; 
 Evaluation of the robustness of the microfluidic method in scale-down or scale-up NPs 
production;  
 Analysis of the effect of microfluidics-associated EFV-loaded PLGA NPs on the metabolic 
activity of BBB endothelial cells and brain parenchyma neuron cells;  
 Study of the hemolytic potential of the nanosystem obtained by microfluidics;  
 Functionalization and characterization of NPs with a transferrin receptor-binding peptide;  
 Evaluation of the interaction of functionalized NPs with BBB endothelial cells;  
 Permeability study of NPs through a BBB in vitro model (including the evaluation of the 
model integrity). 
The nanosystem should be intravenously administered, a posteriori. 
The uppermost concept of this project was to develop ARV-loaded NPs using the microfluidic 
technology as a scalable methodology. Once the setup was defined, including the optimization of 
NPs final properties, to accomplish the desired purpose, the system underwent biological tests and 
was ameliorated to operate in the desired target, leading to a therapeutically effective treatment 
against the pathological case in study, the HIV. 
1.3 Work structure 
This dissertation was organised in five chapters.  
Chapter 1, “Introduction”, was dedicated to explore the motivation for this work and the 
inherent main goals.  
Chapter 2, “State of the Art”, was divided into seven sections: the first related to the CNS, 
where BBB was emphasized; in the second section, a brief reference to BBB in vitro models was 
stated; the third associated with HIV, in particular to the infection mechanism and the incidence in 
CNS; the fourth section presented a brief introduction to the HIV-based ART; in the fifth section the 
use of polymers as biomaterials to be implemented in NPs was discussed; on the sixth section, 
conventionally-performed methodologies were described, namely nanoprecipitation, that allows 
PLGA NPs development; the seventh and last section of this chapter was related to an innovative 
method used in the production of PLGA NPs, the microfluidics, and its applicability.  
Chapter 3, where the “Material and Methods” of the practical work performed were presented 
in detail, so the experiments described can be reproduced by other researchers.  
Chapter 4, “Results and Discussion”, stated the results obtained and respective discussion.  
In the last chapter, “Conclusion”, the main findings of the developed work and future prospects 
were presented. 
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Chapter 2 
State of the Art 
2.1 Central nervous system 
The CNS is composed by the brain and the spinal cord. These structures have sensitive cells 
which need accurate control of their biochemical and immunological milieu, in order to achieve an 
optimal functioning [26, 27]. Some disorders related to the CNS are neurodegenerative diseases as 
Parkinson’s or Alzheimer’s diseases, brain cancer, epilepsy, and severe infections as HIV [28]. 
There are three main boundaries in the brain that protect neuronal microenvironment: the 
blood–cerebrospinal fluid (blood-CSF) barrier, the BBB, and the cerebrospinal fluid-blood (CSF–
blood) interface. Blood-CSF barrier is formed by epithelial cells of the choroid plexus; BBB is shaped 
through cerebral endothelium; and the CSF-blood interface is formed by superposition of dura mater 
and the avascular arachnoid epithelium [16, 29, 30].  
For the purpose of this study, BBB was the main focus. 
 
2.1.1 Blood-brain barrier  
One of the barrier systems that protect and maintain the homeostasis of the CNS in all animals 
with a complex nervous system is the BBB [31]. The BBB main goal is to control the influx of blood-
borne active molecules and cells to the brain [32]. However, BBB is a “bottleneck” in drug 
development for brain target, thus restraining the enlargement of CNS pharmacotherapeutics field 
[33]. 
The BBB covers almost all brain regions, with the exception of circumventricular organs, where 
blood-borne molecules diffusion across the vessel wall is allowed [34].  
The BBB is composed by strongly linked brain microvascular endothelial cells through specific 
junctional structures [2, 31]. Astroglia, pericytes, perivascular macrophages, and a basement 
membrane (also known as basal lamina) surround BBB endothelial cells, thus contributing to the 
maintenance of BBB integrity [31]. Regarding anatomy and functionality, BBB is directly associated 
with brain parenchymal cells, such as neurons [34]. On Figure 2.1, the BBB structure and its 
environment are illustrated. 
Endothelial cells delineate the brain microvessels. These cells interact with the surrounding 
astrocytes, pericytes and neurons, and together they build the so-called neurovascular unit [35]. 
Endothelial cells have highly selective functions due to the inter-endothelial junction network and a 
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particular assortment of transporters, which allow the controlled passage of substances through the 
BBB [36]. Endothelial cell-cell junctions include tight junctions, adherens junctions and gap 
junctions. All of these junctions result from the combination of membrane adhesive proteins that 
allow BBB cohesive structure [37, 38]. Adherens junctions are mainly responsible for regulating cell-
cell contacts [39]; tight junctions regulate solutes and ions diffusion through the paracellular 
pathway [2, 31, 39]; and gap junctions, in turn, mediate intercellular communication by hemi-
channels formation [38, 40, 41]. Besides junctions, the capillary endothelium is characterized by 
the lack of fenestrations, and almost absence of pinocytotic vesicles [34].  
Astrocytes represent around 90% of overall brain mass [42]. They are crucial cells for BBB 
development and maintenance by secreting factors, which provide the adequate association 
between barrier cells and the establishment of strong tight junctions [43]. Among other functions, 
astrocytes are responsible for neurons support, and play a key role in different brain metabolic 
processes [44, 45]. 
Pericytes are contractile cells which encircle the brain capillaries, composed of relatively 
undifferentiated connective tissue [46]. Pericytes association to blood vessels regulates endothelial 
cells survival, migration, differentiation, proliferation, and vascular branching [47].  
Perivascular macrophages are responsible for innate and adaptive immune responses in the brain 
[47]. Literature data suggest that this cell line derives from monocyte lineage [48].  
In addition to BBB cellular components, the extracellular matrix (ECM) is also an important 
structural element. The CNS ECM is formed in the intracellular microenvironment and then secreted 
into the extracellular space, in order to develop a dense molecule network of proteins and glycans 
[49, 50]. It surrounds cells providing both structural and chemical support. The ECM offers 
anchorage points to cells and enables their spatial arrangement. Simultaneously, the matrix is a 
source of external stimulus that conduct the survival, differentiation, growth, and migration of cells 
[51]. The basement membrane is a continuous ECM structure connecting endothelial cells to 
astrocytic endfeet, and it is mostly known for its role in maintaining BBB integrity [51, 52].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 – Structure of the BBB. The principal feature of this barrier is the tight apposition of endothelial 
cells lining blood vessels in the brain. Adapted from [52]. 
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Cells movement across BBB (eg, leukocytes) is a highly regulated process that requires cell- and 
tissue-specific mechanisms. These interactions involve a variety of intracellular and/or extracellular 
molecules and barrier structures, which include cytokines and their receptors, cell adhesion 
molecules, and tight junctions, among others [53]. 
The BBB is also an enzymatic barrier. These enzymes are responsible for neuroactive blood-
circulating solutes metabolization, like drugs or nutrients, and they are often polarized between the 
apical and basolateral surface of endothelial cells [37]. Some examples of these enzymes are γ-
glutamyl transpeptidase, alkaline phosphatase, and aromatic acid decarboxylase [54].  
In general, there is a bidirectional impediment to free diffusion through the BBB [31]. In fact, 
only the lipid-soluble small molecules with a molecular weight < 400 Da [55] and < 8 hydrogen bonds 
formed with solvent water [33] are able to cross the BBB with significant relevance, when driven by 
a concentration gradient and in absence of active transport [34].  
In addition to providing a physical barrier, both apical and basolateral surfaces of endothelial 
cells are able to express molecular efflux and/or influx carriers (Figure 2.2). These are classified in 
carrier-mediated transporters (CMTs), active efflux transporters (AETs), and receptor-mediated 
transporters (RMTs). CMTs and AETs are responsible for small molecules transport, whereas RMTs 
are responsible for large molecules transport [56].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 - BBB transporters. a) CMT; b) AET; c1) RMT transferrin receptor; c2) RMT Fc receptor. Adapted 
from [57]. 
 
Carrier-mediated transporters (Figure 2.2a) are expressed on both apical and basolateral BBB 
side, and thus they catalyze the bidirectional movement of polar nutrients between blood and 
brain, such as glucose, amino acids, monocarboxylic acids, choline, purine nucleosides, thyroid 
hormone and water-soluble vitamins [57]. Each molecule accesses a unique CMT system; this type of 
transport occurs through specialized stereospecific proteins, which means that they display 
significant structural requirements [57, 58]. Some examples of CMTs are glucose transporter 1 
(GLUT1), monocarboxylate transporter 1 (MCT1), L-type amino acid transporter 1 (LAT1) and 
cationic amino acid transporter 1 (CAT1), or concentrative nucleoside transporter 2 (CNT2) [59]. 
Active efflux transporters (Figure 2.2b) are asymmetrically expressed on apical BBB side, and 
thus they mediate the unidirectional efflux of metabolic products and xenobiotics, which include 
drugs, from brain to blood [57]. Some examples of AETs structures are the P-glycoprotein (P-gp) 
transporter and other adenosine triphosphate-binding cassette (ABC) gene family members [60]. 
Receptor-mediated transporters (Figure 2.2c) consist on a group of peptide-specific receptors 
which can be expressed on apical, basolateral, or both BBB side [56, 57]. For example, on one hand 
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the transferrin receptor, represented with number 1 in Figure 2.2c, is a bidirectional system 
(expressed on both BBB side) [61]. On the other hand, the Fc receptor (FcR), represented with 
number 2 in Figure 2.2c, only promote the transport in the brain-to-blood direction (only expressed 
on apical BBB side) [62]. 
Besides transporters, BBB endothelial cells present several ion channels which are involved in 
brain homeostasis and barrier physiology [37].  
The biggest challenge related to the treatment of diseases involving the CNS is the effective 
delivery of drugs across the BBB [2]. It is known that 100 % of large-molecule drugs and > 98 % of 
small-molecule drugs cannot surpass it [55]. Moreover, as previously mentioned, a successfully 
diffusion trough the BBB implies a drug lipid-soluble profile. Pharmaceutical industry has been 
trying to manipulate the BBB permeation by changing the water-soluble profile of drugs with 
therapeutic relevance for the CNS to a lipid-soluble one. However, this may rise variations in 
pharmacokinetic and chemical stability properties that enable successful therapies [63]. Besides 
size and solubility, drugs that are highly bound to plasma proteins are also less available to cross the 
BBB [64]. One possible solution to overcome these problems seems to be the exploitation of 
endogenous BBB transporters [55]. Drug structure can be modified to increase its affinity for one of 
several CMT or RMT systems that normally serves to mediate the brain uptake of natural molecules 
[63].  
2.2 Blood-brain barrier in vitro models 
Blood-brain barrier in vitro models present a useful tool to predict the ability of therapeutic 
compounds to permeate this biological barrier. This tool is also extremely important to study the 
effectiveness of nanotechnology-based products to deliver drugs across the BBB, hence allowing the 
identification of the optimal formulation parameters to be applied in in vivo studies [65]. 
In vitro models may be based on a cellular or non-cellular structure. Cellular-based models are 
able to express different physiological drug transport mechanisms and metabolic enzymes, allowing 
the inclusion and study of different permeability pathways [66]. Non-cellular-based models consist 
on artificial membranes, as phospholipid vesicle-based permeation assay (PVPA), and are only able 
to study the passive diffusion of drugs by passive transcellular-like permeability. Non-cellular 
models are cheaper, less time-consuming, easily reproducible, and do not present contamination 
problems compared to their cellular-based counterparts [67, 68]. However, cellular-based in vitro 
models are usually preferred since an ideal structure for a BBB in vitro model should comprise a 
morphology very similar to the in vivo cellular one, restrictive paracellular transport (well-defined 
tight junctions), expression of specific transporters, efflux mechanisms and enzymes [69]. 
Afterwards, the model should be able to closely mimic the in vivo environment of the BBB. It is 
important to mention that cellular-based BBB in vitro models also present disadvantages, as the 
associated costs of maintenance, time spent in cell culture, and difficulties in obtain reproducible 
results [68].  
The simplest cellular-based BBB model consists on a monoculture of brain endothelial cells, the 
major cellular component of the BBB, cultured on an insert membrane (Transwell® system). Besides 
the simplicity, this model is considered appropriate for the initial screening of drugs permeability 
[69].  In order to increase the degree of resemblance with the biological structure of the BBB and its 
evironment, another cell types can be included, as astrocytes, neurons, or pericytes. They can be 
co-cultured in the basolateral compartment, either in contact (cultured in the basolateral side of 
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the insert membrane) or non-contact (cultured in the bottom of the well) [65]. Figure 2.3 
demonstrates some examples of BBB in vitro models.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 – Schematic representation of in vitro cell-based models of the BBB using Transwell® systems to be 
applied in permeability studies of nanotechnology-based products. a) Triple co-culture of endothelial cells, 
astrocytes and neurons; b) non-contact co-culture of endothelial cells and astrocytes or neurons; c) contact co-
culture of endothelial cells and astrocytes or neurons. Adapted from [65]. 
 
Still, challenges remain. The in vitro models currently employed in the biomedical research 
field are far from the ideal structure, mainly due to the in vivo complexity of the BBB which is 
difficult to mimic. It would be important to improve these models, keeping a balance between the 
degree of resemblance, ease of development and applicability [65] 
2.3 Human immunodeficiency virus 
By the end of 2015, World Health Organization (WHO) estimated that 37 million people in the 
world were living with HIV [70]. HIV disease is caused by an infection with human immunodeficiency 
virus type 1 (HIV-1) or human immunodeficiency virus type 2 (HIV-2), which are retroviruses of the 
Retroviridae family, Lentivirus genus [71]. 
The virus infects and destroys immune cells, thus increasing susceptibility to infection and 
disease, and over time this can lead to AIDS [4].  
The HIV is a blood-borne virus transmitted via sexual intercourse (vaginal, anal, or in a minor 
contribution, oral sex); shared intravenous drug paraphernalia (needles, syringes, or other sharp 
instruments); mother-to-child transmission when the mother is already HIV-positive, which can 
occur during pregnancy, childbirth or breast-feeding; and through blood transfusion [72, 73]. 
The HIV-1 is the most virulent type (commonly denoted only as HIV) [73]. Although the two 
types of virus share the same transmission routes, HIV-2 is not as easily transmitted as HIV-1. The 
HIV-2 takes more time from infection to AIDS, it has a longer latency period, and low or 
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undetectable plasmatic viral levels [74]. Moreover, HIV-1 is predominant worldwide, whereas HIV-2 
is typically confined to West Africa [75, 76]. The mortality rate related to HIV-1-infected individuals 
is significantly higher than that related to HIV-2-infected ones [77]. Both HIV-1 and HIV-2 have an 
identical structure, and the virus-induced disease pathogenesis is also very similar [78].  
 
2.3.1 Infection process  
The HIV infects blood circulating cells containing HIV key receptors, which are mainly the CD4 
(cluster of differentiation 4; immune cells receptor), but also CD8 (cluster of differentiation 8; co-
receptor of T-cells receptor (TCR)), and various chemokine-receptors (HIV co-receptors). They help 
virus attachment to cells and promote the fusion of viral envelope with cell membrane. Therefore, 
virus capsule, which includes virus ribonucleic acid (RNA) and viral enzymes RT, integrase (IN), and 
protease (PR), enters the cytoplasm [79]. Each virus particle comprises two identical RNA copies of 
the genome [71]. After entry into the cell and due to the action of RT, the virus undergoes reverse 
transcription of its RNA genome into a double-stranded deoxyribonucleic acid (dsDNA). The IN then 
facilitates dsDNA integration into the host chromosome. By using the cellular replication machinery, 
provirus (HIV deoxyribonucleic acid (DNA)) replicates along with the chromosome when the cell 
divides [80]. Every time the provirus is transcribed, new viral RNA and proteins are produced using 
the host cell protein-making system [81]. The PR participates by processing the recently translated 
polypeptides into proteins, which are then assembled into viral particles [82]. At this point in time, 
the virus is able to bud out of the cell and proceed with its dissemination, acquiring a phospholipid 
envelope [83]. Figure 2.4 summarizes HIV infection process. 
 
 
 
Figure 2.4 - HIV cell infection. 1) Virus and host cell membrane fusion; 2) viral RNA reverse transcription to 
DNA; 3) viral DNA incorporation into the host chromosome (provirus); 4) viral particles production; 5) viral 
particles bud out of the host cell. Adapted from [84]. 
 
2.3.2 Central nervous system invasion  
The CNS is susceptible of infection by retroviruses of different species, especially by members of 
the lentiviruses family [85]. The HIV is a multisystem disorder that includes the CNS, among others 
human body systems. 
The HIV is known to invade the CNS compartment from systemic circulation in an early stage of 
infection. This can be done through the blood-CSF barrier as cell-free viral particles [86], through 
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the infection of BBB endothelial cells or astrocytes and then transfer via these cells to the CNS, 
through the extracellular movement of the virus across a disrupted BBB [53], or through the BBB in 
form of peripherally infected leukocytes, mainly monocytes, a so-called “Trojan horse” mechanism 
[16, 86]. The last one is the most accepted model for HIV entry into the CNS (Figure 2.5) [87].  
Several infected leukocytes circulate in the blood stream as an HIV effect. Simultaneously, 
there is a dysregulation of chemokines secretion and chemokines receptors in HIV-infected patients. 
This family of chemokines play a crucial role in the pathogenesis of the disease, facilitating 
leukocyte transmigration through the BBB to CNS in response to chemokine gradients [53]. 
Moreover, HIV increases the expression of adhesion molecules, which facilitates leukocyte binding 
and diapedesis across this barrier [88]. After crossing the BBB, HIV-infected cells propagate the 
infection within the CNS. Monocytes can become perivascular macrophages, and then produce new 
viral particles and spread productive HIV infection to neighboring microglia [89]. These two types of 
cells provide the site for HIV replication and evolution in the brain parenchyma [90]. They can also 
release a variety of neurotoxic host factors that contribute to neuronal injury [91] and activation of 
other CNS cells, such as astrocytes. When activated, astrocytes are able to increase the BBB 
permeability, and thus this leads to an increase in “Trojan horse” leukocytes influx  [64]. Viral 
proteins expressed in the surface of HIV-infected cells appear to be responsible for the fusion of 
microglia and/or macrophages to result in the formation of giant multinucleated cells, the hallmark 
cells of brain parenchyma inflammation [79, 92]. Although neurons and oligodendrocytes are rarely 
infected [53], neuronal dysfunction throughout CNS, mainly related to axonal and dendritic pruning, 
is a very common HIV outcome [93].  
In addition to the infection process, there are several complications associated with AIDS 
neuropathogenesis. This involves an inflammatory cascade which results from the modification of 
HIV-infected cells secretory functions, stimulated by the virus. They produce neurotoxic molecules, 
including cytokines and reactive oxygen species, that disrupt normal cellular functioning and modify 
neurotransmitters action [79]. 
 
 
 
Figure 2.5 - “Trojan horse” mechanism. a) HIV enters the brain mainly through its presence in infected 
monocytes that migrate across the BBB; b) the virus that is produced in the brain compartment is mainly 
derived from monocytes which have differentiated into perivascular macrophages, but infected microglia can 
also contributes to the production of virus; c) the HIV-envelope glycoproteins expressed at infected cells 
surface are able to mediate cell-to-cell fusion, thus resulting in the formation of large multinucleated giant 
cells which produce virus; d) HIV can also enter the brain through its presence in infected CD4+ T cells; e) it is 
generally accepted that infection of astrocytes cells is not productive, and thus they do not contribute to viral 
replication. Adapted from [87]. 
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2.4 Human immunodeficiency virus-associated antiretroviral therapy  
The number of HIV-infected people enrolled in ARTs has been clearly increasing since 2005, at 
the same time as HIV-related deaths started decreasing (Figure 2.6) [70]. The HIV treatment 
involves taking medicines, known as ARVs, which slow the progression of the virus in human body, 
and thus they offer several life-saving and life-prolonging benefits to HIV-infected individuals. These 
drugs are usually given in combination, which is called an ART [94].  
Regarding HIV infection clinical profile, ART became possible to turn a subacute lethal disease 
into a chronic ambulatory disease [95]. Current therapies are not able to eradicate the virus, thus 
ART goals are to achieve and maintain viral RNA at a low blood concentration, avoiding the 
formation of new viral particles and decelerating the damage to the host immune system [95-97]. 
The ART restores the immune function by increasing CD4 cells count and providing viral 
replication suppression to nearly undetectable levels, which can be maintained for years [95]. 
Consequently, this smooths HIV-related symptoms and prevents the appearance of opportunistic 
pathologies [79].  
 
   
 
Figure 2.6 - Worldwide ART coverage and number of AIDS-related deaths between 2000 and 2015. Adapted 
from [70]. 
 
Antiretroviral therapies are based upon at least three anti-HIV medications that may belong to 
different drug classes [98]. The main ARV classes are nucleoside reverse-transcriptase inhibitors 
(NRTIs), nucleotide reverse-transcriptase inhibitors (NtRTIs), non-nucleoside reverse-transcriptase 
inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), protease inhibitors (PIs), and entry 
inhibitors (EIs) [99]. Table 2.1 summarizes their therapeutic action. 
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Table 2.1 — Properties of drugs commonly applied in HIV treatment. 
Drug class Drug action References 
NRTIs or 
NtRTIs 
Analogues of nucleosides (NRTIs) or nucleotides (NtRTIs) which act as 
substrates for the RT. NRTIs and NtRTIs inhibit the enzyme by competing 
with endogenous nucleosides or nucleotides, respectively, for integration 
into the growing proviral DNA chain. Viral replication ceases without the 
presence of a hydroxyl group in the drug structure, hence avoiding the 
addition of another nucleoside (NRTI) or nucleotide (NtRTI). 
[7, 8] 
NNRTIs 
These medicines are non-competitive inhibitors of the RT. They specifically 
bind to RT, near enzyme active site (allosteric inhibition). Consequently, the 
enzyme is locked in an inactive conformation and this reduces the binding of 
natural nucleosides. 
[7-9] 
 
INSTIs 
Drugs that interact with IN catalytic core domain by combining with its 
divalent metal ions to form a chelate, hence blocking enzyme role in HIV 
pathogenesis. 
[100, 101] 
PIs 
PIs inhibit the PR by mimicking the cleavage sites of retroviral polyprotein 
precursors and competing with them for the enzyme at a late stage of viral 
replication. Although HIV can still replicate in the presence of PIs, this leads 
to immature, non-infectious virus particles production. 
[7, 102] 
EIs 
Drugs that are able to avoid entry of virus into host cells, affecting one of 
three phenomena: receptor binding, coreceptor binding, and membrane 
fusion. Currently, only compounds related to the last two strategies have 
been approved by FDA. 
[103] 
 
NRTI: nucleoside reverse-transcriptase inhibitor; NtRTI: nucleotide reverse-transcriptase inhibitor; NNRTI: non-
nucleoside reverse-transcriptase inhibitor; INSTI: integrase strand transfer inhibitor; PI: protease inhibitor; EI:  
entry inhibitor. 
 
2.4.1 Antiretroviral drug model: efavirenz 
The 2016 WHO treatment guidelines for adult HIV-1 infection recommend the NNRTI EFV for a 
standard first-line ART, in combination with the NRTIs tenofovir and either lamivudine or 
emtricitabine [104].  
Efavirenz, formerly known as DMP-266, is an antiviral drug and was approved by FDA in 1998, for 
use in combination with other ARV agents for HIV treatment [6]. This API, whose empirical formula 
consists on C14H9ClF3NO2 (Figure 2.7) [105], has a hydrophobic structure and a molecular weight of 
315.68 g.mol-1 [106-108]. According to the Biopharmaceutics Classification System, EFV is classified 
as a Class II API, which means that it is poorly soluble (aqueous solubility less than 10 mg/mL) and 
highly permeable across biological membranes [109].  
 
14  State of the Art 
 
 
 
Figure 2.7 - Efavirenz structural formula. Reprinted from [110]. 
  
The pharmacokinetic of EFV appears to be similar between different genders and races. EFV is 
mostly metabolized in the liver to inactived hydroxylated metabolites, through a process involving 
the cytochrome P450 enzymatic system [111]. Following a single dose of 600 mg in adults, it is able 
to reach a peak plasma concentration of 4.1 mg/L in 3–5 h, and after multiple dosing, steady-state 
concentrations are achieved between 6 and 10 days [107]. Moreover, this drug has a poor 
bioavailability of nearly 40 % [106]. Serum EFV is highly protein bound (> 99 %), predominately 
albumin-bound, which hinders drug extravascular diffusion and allows its high intracellular and 
plasma concentration [107].  
The ability of ARV drugs to reach the CNS (or to cross the BBB) can be evaluated based on two 
main complementary measures: cerebrospinal fluid:blood plasma concentration ratio (CSF:BP), also 
referred to as cerebrospinal fluid (CSF) penetration, and CNS penetration effectiveness scoring 
system (CPE) [112]. The choroid plexus allows drug movement from blood to CSF, and it is a leaky 
structure compared to the BBB. Drug entry into CSF is expected, a process that occurs through 
simple diffusion of the drug unbound form [107], and is not able to discriminate between drugs that 
cross, or not, the BBB [113]. This is the reason to consider not only one measure. CPE resulted from 
the studies of Letendre et al. [114, 115] and consists on a theoretical concept based on physico-
chemical, pharmacokinetic and pharmacodynamic properties of each drug [116]. Its updated version 
is presented in four categories, ranging from 0 (worst CNS estimated penetration) to 4 (better CNS 
estimated penetration). Table 2.2 summarizes the CSF:BP and CPE for the main drugs applied to 
ARTs. As can be seen , the CSF:BP of EFV can vary between 0.003 and 0.01, and this drug belongs to 
CPE category 3 [117]. Although EFV levels in CSF are considered low, they are frequently above 50 % 
inhibitory concentration (IC50; API concentration where 50 % of viral replication is inhibited), which 
has the value of 0.5 ng/mL for this drug [64, 117].  
There is no evidence of EFV association with any influx or efflux BBB transporters [118, 119]. 
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Table 2.2 - CSF:BP and CPE for the main drugs applied to ARTs. Adapted from [16, 117].  
Drug class Drug CSF:BP CPE References 
NRTIs 
Zidovudine 0.50 4 [120] 
Didanosine 0.21 2 [121] 
Stavudine 0.16-0.40 2 [122, 123] 
Lamivudine 0.06-0.23 2 [123, 124] 
Abacavir 0.18-0.36 3 [125] 
Emtricitabine 0.26 3 [126] 
NtRTIs Tenofovir 0.05 1 [126, 127] 
NNRTIs 
Nevirapine 0.63 4 [123] 
Efavirenz 0.003-0.01 3 [112] 
Etravirine 0.01 2 [128] 
INSTIs 
Raltegravir 0.01-0.61 3 [129] 
Dolutegravir 0.50 Not available [130] 
PIs 
Saquinavir ≤ 0.002 1 [131, 132] 
Indinavir 0.11 4 [123] 
Atazanavir 0.002-0.014 2 [133] 
Fosamprenavir 0.012 2/3 [134] 
Darunavir 0.01 3 [135] 
EIs 
Enfuvirtide Undetectable in CSF 1 [136] 
Maraviroc 0.025 3 [137] 
 
CSF:BP: cerebrospinal fluid:blood plasma concentration ratio; CPE: central nervous system penetration 
effectiveness scoring system; NRTI: nucleoside reverse-transcriptase inhibitor; NtRTI: nucleotide reverse-
transcriptase inhibitor; NNRTI: non-nucleoside reverse-transcriptase inhibitor; INSTI: integrase strand transfer 
inhibitor; PI: protease inhibitor; EI: entry inhibitor; CSF: cerebrospinal fluid.  
2.5 Polymers as biomaterials: application in nanoparticles 
A biomaterial can be defined as a “material intended to interface with biological systems to 
evaluate, treat, augment or replace any tissue, organ or function of the body” [138]. The most 
important requirement of a biomaterial is its biocompatibility, whose definition was provided by 
Williams in a consensus conference as follows “the ability of a material to perform with an 
appropriate host response in a specific application” [138]. It is associated to the response of the 
immune system after the introduction of the material and toxicity due to possible metabolites 
resulting from its degradation [139]. Biocompatibility is not expected as an intrinsic property of 
biomaterials. In fact, it depends on the biological environment and tolerability related to specific 
interactions with the tissues [140]. Another requirement desirable for a biomaterial is its 
biodegradability, which is a key parameter for its acceptance by regulatory authorities [141]. A 
biomaterial is called biodegradable when the products of its degradation are metabolizable in the 
body and excreted naturally afterwards [142]. 
Polymers are the most multifaceted class of biomaterials that are commonly applied in 
biomedical applications, ranging from surgical sutures to tissue engineering scaffolds, medical 
16  State of the Art 
 
implants, and DDSs [143]. Due to the versatility and ease with which they can be processed, 
polymers are quickly replacing other material classes, such as metals, composites, and ceramics for 
use as biomaterials [144]. Polymeric materials have a large molecular mass relative to their 
monomers, and thus, this contributes to their typical physical properties, including toughness, 
viscoelasticity, and a tendency to form amorphous structures [145]. Polymers are formed by long 
chains of repeated molecules via monomers polymerization [146]. Polymers chemical bonds consist 
of primary bonds, which are covalent bonds involving two atoms sharing electrons, and secondary 
bonds, which include van der Waals forces, hydrogen and ionic bonds [145].  
Nanoparticles, as DDSs, built with polymeric biomaterials have gained attention from the 
scientiﬁc community as a result of their controlled and sustained release properties, subcellular 
size, feasibility of production and biocompatibility [147]. One desirable aspect in the field of NPs 
development is to use polymers already approved by FDA and European Medicine Agency (EMA) [148, 
149]. In these nanosystems, the therapeutic substance may be encapsulated, adsorbed or dispersed 
in the NPs [150]. 
The first classes of polymers explored for NPs as DDSs were the non-biodegradable polyacrylics, 
poly(vinyl chloride-co-acetate) (PVCA) and polystyrene [146, 151]. The polymeric NPs built with 
these polymers do not disaggregate in the body and release drugs by passive diffusion in a slowly 
way [146]. Later on, polymeric NPs based on biodegradable materials were explored, since the 
polymers chains are capable of degrading in vivo, either enzymatically, non-enzymatically or both 
[146, 152]. Using these polymers, the production of a DDS, which releases an active agent during a 
predetermined time interval, is possible by selecting a specific polymer composition with a known 
rate of degradation [153]. Furthermore, the release is regulated by both passive diffusion of drugs 
and polymer breakdown [146]. In most of the cases, the products resulting from the degradation of 
these polymers are biocompatible and therefore toxicologically safe [152]. Some examples of 
biodegradable polymers are the poly(lactic acid) (PLA), poly(glycolic acid) (PGA), PLGA, 
polycaprolactones and polyacrylates [151]. 
Usually, polymeric NPs are classified into nanospheres and nanocapsules. Nanospheres are 
structures in which the drug is physically and uniformly dispersed in a matrix. Nanocapsules have a 
vesicular type structure in which a drug is confined to a cavity (liquid core) surrounded by a polymer 
membrane (polymeric shell) [55, 154]. This principle is demonstrated in Figure 2.8.  
 
 
 
Figure 2.8 – The two types of polymeric NPs. Nanospheres present a polymeric matrix and nanocapsules 
present a vesicular-like structure. Reprinted from [155]. 
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2.5.1 Poly(lactic-co-glycolic acid)  
The PLGA is an aliphatic polyester copolymer of lactic acid (LA) and glycolic acid (GA), whose 
forms are usually identified by the ratio between these two monomers, also biodegradable [156]. 
They result from the hydrolysis of PLGA and are forwarded to natural metabolic pathways, as 
demonstrated in the Figure 2.9. In a biochemical point of view, the Krebs cycle is the mechanism 
responsible for LA and GA degradation and bioelimination inside the human body [23].  
The arrangement of different GA building blocks originates PGA, which is the simplest linear 
aliphatic polyester. Still, PGA biomedical applications are limited due its low solubility and high rate 
of degradation yielding acidic products [157]. The arrangement of different LA building blocks 
originates PLA, and this polymer also belongs to the family of aliphatic polyesters [158]. Lactic acid 
can exist in optically active D– or L-enantiomers, and depending on the proportion of these 
enantiomers, PLA of variable material properties can be derived [159]. Lactic acid is more 
hydrophobic than GA, thanks to the presence of –CH3 side groups. This means that it will absorb less 
water and present slower degradation rates [160]. Therefore, high ratios of LA:GA in PLGA 
compounds increase the time interval of degradability of this copolymer [152]. 
The properties of PLGA have turned it in one of the most attractive candidates in the field of 
biodegradable and biocompatible polymeric NPs as DDSs, since it has been considered the best 
tailored biomaterial for this purpose with respect to design and performance [152, 161-166]. This 
polymer can be processed into any shape and size, and can encapsulate biomolecules of a wide size 
range [167]. The application of PLGA in humans was already approved by FDA and EMA for the use in 
DDSs for parenteral administration, diagnostics and other applications of clinical and basic science 
research (cardiovascular diseases, cancer, vaccines and tissue engineering) [168, 169]. The PLGA 
has a good mechanical behavior [152], and it has also demonstrated low toxicity [23, 170]. This 
polymer degrades by hydrolysis of its ester linkages, through bulk or heterogeneous erosion, in 
aqueous environments [167].  
 
 
 
Figure 2.9 - Hydrolysis of PLGA in acidic medium. LA and GA are forwarded to natural metabolic pathways, 
such as the Krebs cycle. m and n are the number of GA and LA units, respectively. Adapted from [167, 170]. 
2.6 Conventionally-performed techniques to develop poly(lactic-co-
glycolic acid) nanoparticles 
In accordance with the classical nucleation theory, the two main steps involved in particulate 
systems development are nucleation and, then, particle growth. Both steps are triggered and 
strongly dependent on the mixing of the formulation components [171]. The rate and effectiveness 
of mixing will determine the size and size distribution of the generated particles. Therefore, 
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particles production method is crucial for their physico-chemical profile, which, in turn, will 
determine the behavior of the DDS [172].  
One of the main strategies used in PLGA NPs formulations is the bottom-up approach. The 
bottom-up techniques are based on the growing of NPs from molecules in solution [173]. Among all 
the applicable procedures related to the bottom-up techniques, the nanoprecipitation is very usual 
for the encapsulation of hydrophobic drugs. For the purpose of this study, this technique will be 
focused.  
 
2.6.1 Nanoprecipitation technique 
The nanoprecipitation technique (also termed solvent displacement) as a way to produce NPs 
was first reported in a patent by Fessi and co-workers, in which they refer the production of 
spherical NPs  with a size under 500 nm [174, 175]. 
Basically, two systems are needed: a semipolar solvent (commonly referred as water-miscible), 
in which both the polymer and the API are soluble (dispersed phase, organic phase or oil), and a 
non-solvent, miscible with the previous one but not allowed to dissolve neither the polymer nor the 
hydrophobic API (continuous phase, aqueous phase or water), consisting in a solution surfactant 
[162, 176, 177].  
The choice of the organic solvent is decisive in developing a successful formulation of particles 
containing an API. Two main solvent features should be considered, namely the ability to dissolve 
both polymer and drug, and its toxicity if residual molecules are present in the final formulation 
[178]. Available solvents have been classified according to their toxicity on three classes: Class I 
(solvents to be avoided), Class II (solvents to be limited) and Class III (solvents with low toxic 
potential) [179]. For safety reasons and since there will always exist residual amounts of solvent in 
the final formulation [178], Class III solvents are the most suitable ones for physiological 
applications. Some examples of organic solvents commonly used in this technique are acetone, 
acetonitrile, N,N-dimethylformamide (DMF), tetrahydrofuran (THF), dichloromethane (DCM), and 
dimethyl sulfoxide (DMSO) [180].  
In order to improve the production methodology, a surfactant should be added. Its role is to 
stabilize the nanosystem during the intermediate steps of the process and there are different 
possibilities for this component, such as TWEEN®, sodium dodecyl sulfate (SDS), polyvinyl alcohol 
(PVA), hydroxymethylcellulose (HPMC) or Pluronic® F-68 [181].  
The first step consists in the preparation of the dispersed phase; here, the polymer and the API 
are mixed with a specific solvent. The second step consists in the preparation of the continuous 
phase, containing just the surfactant (non-solvent). Afterwards, the dispersed phase is slowly added 
to the continuous one [182].  
The formation of NPs occurs spontaneously due to the inter-diffusion of the organic solvent into 
the surrounding continuous phase medium [162, 183]. This results in the decrease of interfacial 
tension between the two phases, a phenomena based on a constant formation of eddies of solvent 
at that local. Consequently, it can increase the surface area and lead to the formation of small 
drops of organic solvent [184, 185]. The magnetic stirring is considered a sufficient mechanical 
agitation procedure [176, 183, 184]. 
The nanoprecipitation is a straightforward method, results in an instantaneous formation of NPs, 
and is easy to perform [163, 176, 184]. Moreover, in general, this technique is associated with a 
better reproducibility compared to emulsion-based techniques. 
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2.7 Microfluidics: an alternative method to produce poly(lactic-co-
glycolic acid) nanoparticles 
Microfluidics is a multidisciplinary field intersecting science and technology, that deals with the 
manipulation of nanoliter volumes of fluids in channels ranging from tens to hundreds of 
micrometers [186]. A research boom in the field of microfluidics has been observed over the last 
years, and this technology demonstrated to be a useful tool to develop innovative drug delivery 
systems.   
The application of microfluidics to the biological area started in 1950, when it appeared for the 
first time associated with gas chromatography and capillary electrophoresis experiments [187]. 
Nowadays, the devices built based on this concept demonstrate ability to address different domains 
of research, such as biological analysis [188], chemical synthesis [189], tissue engineering [190], or 
pharmaceuticals [191]. In the field of nanomedicine, different microfluidic approaches are being 
developed in order to produce DDSs, especially NPs [11, 192-197]. 
Alternatives to the conventional bulk methods that have been used to produce drug-loaded NPs 
emerged through the need for precise control of their properties. Some of the most common 
problems reported are the inability to control the mixing process [194]; poor drug loading [198] and 
consequent consumption of considerable amounts of expensive APIs to reach the desired 
therapeutic effect [199]; lack of reproducibility noted from batch-to-batch properties, namely in 
particles average size, size distribution, charge and drug release behavior [200]; and large 
polydispersity in size of particulate systems [201]. The monodispersity of NPs formulations is of 
major importance in determining the performance of particles as drug carriers, because it 
influences biodistribution, cellular uptake and drug release profile [195]. The outstanding outcomes 
in monodispersity of formulations associated with microfluidics are related to a better control of 
the steps involved in particles formation, nucleation and growth [171]. In the conventional 
methodology, stirring, shaking or sonicating are usually the mechanisms responsible to perform the 
mixing of the different phases. This involves an unstable ratio between the phases, heterogeneous 
environments and polydispersity of formulations. Moreover, the mixing is usually slow and 
incomplete, leading to adsorption of the polymers to aggregates of particles and a consequent 
increase in NPs final Z-average. In microfluidics, the mixing is usually faster than the time necessary 
to occur NPs nucleation and growth. Therefore, the polymer is not able to adsorb to recently-
formed NPs, and ends up forming more particles with a smaller size [194, 202]. Besides the 
capability of obtaining a better control over the above mentioned parameters, recently microfluidic 
devices are gaining attention due to saving costs and time [11]. Furthermore, there is the possibility 
of varying key parameters, such as the flow rates, mixing time or channel diameters, in order to 
obtain formulations with tunable final properties [194]. Since the production process of NPs by 
microfluidics is continuous, this contributes to the reduction of batch-to-batch oscillations in 
relation to the final properties of the nanosystems [202]. The accurate manipulation of fluids and 
their laminar regimen inside the microchannels lead to the preservation of controlled hydrodynamic 
conditions, which are rapidly defined and kept during the process of formation of particles [171, 
197]. Figure 2.10 illustrates some of the most appealing features of microfluidics to fabricate drug 
delivery carriers.  
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Figure 2.10 - Some of the most outstanding features associated with the microfluidic technology to produce 
drug delivery carriers. Reprinted from [202]. 
 
Yet, it is important to mention that big challenges remain. First of all, the translation from 
academic research to industry is a crucial step [186, 203] and this is only possible by turning this 
process into a scalable one. Generally, the reactors present small sizes and are associated with low 
flow rates [171]. Thus, the production could be scaled-up by introducing parallel microfluidic 
devices - only in this way it will be possible to reach units of rate production of kilograms per hour, 
instead of grams per hour [192, 197, 201].  In terms of performance, the danger of clogging of the 
channels with trapped small particles or precipitates is also a disadvantage [204].  
 
2.7.1 Microfluidics platforms layout 
A general microfluidics device should be constituted by a substrate, channels and pumps, such 
as syringe or peristaltic pumps, to generate pressure-driven flows through each channel [195, 203]. 
The typical materials used for the substrate are polydimethylsiloxane (PDMS), glass and silicon 
[187]. The channels used to introduce solutions into the device are called inlets. In opposition, the 
channels used to collect the recently formed particles from the device are called outlets [192, 196]. 
By increasing the number of the last ones, the production speed of NPs can be improved [192]. The 
inclusion of valves and reservoirs in the devices is also conceivable [204].  
Microfluidic platforms may adopt different geometries, and the main ones are presented in 
Table 2.3.  
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Table 2.3 — Microfluidic platforms geometries.  
Geometry Design Principle References 
Hydrodynamic 
flow-focusing  
 The flow-focusing geometry is associated with a 
combined two-phase flow that is forced to pass 
through a small orifice.  
In this case, the DP flows through the inner 
capillary, whereas the CP flows through the outer 
capillary in the same direction. Then, both fluids 
are forced to flow through a small orifice. In 
consequence, the CP exerts shear stress that 
forces the DP into a narrow thread. DP ends up 
breaking into particles inside or after the orifice. 
[205, 206] 
Hydrodynamic 
flow-focusing 
(adapted) 
 The two phases, CP and DP, are injected through 
the two ends of the same outer capillary but in 
opposite directions. Then, particles are collected 
from another, coaxially aligned, inner capillary. 
When the phases meet at the constriction place, 
the outer fluid may squeeze the inner fluid which 
breaks into spherical drops, and the DP may form 
a liquid thread in the core of the CP due to the 
symmetric shearing force imposed by CP. 
[194, 205, 
207-209] 
Co-flow 
 Two capillaries are coaxially aligned. The DP is 
injected through the inner capillary, whereas the 
CP is injected through the outer capillary but in 
the same direction. Drops are formed at the 
inner capillary orifice where the DP meets with 
the sheath CP, under the competition between 
shear force and surface tension provided by the 
outer phase. 
[201, 205, 
210-212] 
 
 
 
T-junction  
This microfluidic geometry is considered the 
simplest one. The CP is injected through the 
main channel, whereas the DP is injected through 
the perpendicular inlet channel. CP-induced 
shear stress and evolution of the emerging drop 
upstream pressure start distorting the DP in the 
downstream direction until its break up into a 
particulate system. 
[205, 210] 
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Cross-junction 
(X-junction)  
The two phases flow in perpendicular directions, 
which creates a focused DP in a CP stream. 
[205, 210, 
213] 
 
Y-junction 
 
 
The two phases are injected through two 
separate inlets, and the product is removed using 
a common outlet. 
[205, 214] 
 
DP: dispersed phase; CP: continuous phase. 
 
2.7.2 Droplet microfluidics 
Although it will not be approached in this work, droplet microfluidics is an area extremely 
important in the field and thus it cannot be forgotten during this literature review section. Unlike 
the subject of this dissertation, which is focused on precipitation microfluidics and miscibility of the 
dispersed and continuous phase, droplet microfluidics, in turn, work in the basis of emulsions or 
immiscibility of the phases involved in NPs production [202, 215]. One of the most interesting 
applications of this type of microfluidics is the assembly of particulate systems with a core/shell 
structure, involving more than one emulsion. The co-flow, flow-focusing, and T-junction are the 
most used geometries in droplet microfluidics. Different or equal geometries can be combined in 
the same microfluidic chip, or the precursor phases can pass through different chips, originating 
complex layouts of the platforms or reactors which are used to produce these structures (Figure 
2.11) [205]. Herein, three different fluids or phases are needed: the inner phase, the middle phase, 
and the outer phase. Particles resulting from these reactors present a core of inner phase 
surrounded by a shell of middle phase. Moreover, the outer phase has to be immiscible with the 
middle phase, and the middle phase has to be immiscible with the inner phase [216]. Nie et al. 
developed a microfluidic platform which combined the co-flow and flow-focusing geometries (Figure 
2.11a) [217]; the primary emulsion was formed in the co-flow system at the inner capillary orifice 
where the inner phase met with the middle phase, and it was then focused in the orifice of the 
flow-focusing system by the outer phase. Utada et al., in turn, established a different system but 
consisting on the combination of the same geometries (Figure 2.11c) [216]. Seo et al. manufactured 
a reactor which combined two consecutive flow-focusing systems (Figure 2.11b) [218]. The inner 
and middle phases were introduced in the first flow-focusing system, resulting in a primary 
emulsion. The thread of the primary emulsion was then focused in the orifice of the second flow-
focusing system by the outer phase, where it broke and released the droplets. Abate et al. 
developed a platform combining two sequential cross-junction geometries (Figure 2.11d) [219]. The 
inner phase was injected into the central inlet, and the middle phase was injected into the side 
inlets of the first cross-junction system. The outlet of the first system, which contained the primary 
emulsion, fed the inlet of the second cross-junction system. 
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Figure 2.11 – Microfluidic platforms combining more than one geometry. a,c) co-flow and flow-focusing 
systems; b) two consecutive flow-focusing systems; d) two consecutive cross-junction systems. IP: inner phase; 
MP: middle phase; OP: outer phase. Adapted from [205]. 
 
 25 
Chapter 3 
Materials and Methods 
3.1 Materials and cell lines 
PLGA (Purasorb PDLG 5004A; 50:50 lactic:glycolic molar ratio; molecular weight around 40 kDa) 
was kindly provided by Corbion. Immortalized human cerebral microvascular endothelial cell line 
(hCMEC/D3 cell line) was purchased from Cedarlane, and mouse neuroblastoma × rat dorsal root 
ganglion neurone hybrid cell line (ND7/23 cell line) was kindly provided by Dr. Pedro Moreno 
(Institute of Health Innovation and Research, University of Porto, Portugal). Transferrin receptor-
binding 12-amino acids peptide (Thr-His-Arg-Pro-Pro-Met-Trp-Ser-Pro-Val-Trp-Pro) was purchased 
from Eurogentec.  
TWEEN®-80, hydrocortisone, ascorbic acid, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), basic fibroblast growth factor (bFGF), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), glycerol, 6-coumarin (6-C), acetic acid glacial, 2-(N-morpholino)ethanesulfonic acid 
(MES), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), 
Histopaque, paraformaldehyde, sodium chloride, and bovine serum albumin (BSA) were acquired 
from Sigma-Aldrich; EFV from BDR Lifesciences; DMSO from VWR; endothelial basal medium 2 (EBM-
2) and high glucose with ultraglutamine Dulbecco's Modified Eagle medium (DMEM) from Lonza; 
acetonitrile, Coomassie Reagent, and versene from Thermo Fisher Scientific; Triton X-100 from Spi-
Chem; fetal bovine serum (FBS), penicillin-streotomycin, chemically defined lipid concentrate, 
Hank's Balanced Salt Solution (HBSS), rat tail collagen type I, and acetic acid, from Gibco; 
glutaraldehyde from AGAR Scientific; sodium cacodylate from Fluka; ethanol from Valente e 
Ribeiro, Lda; wheat germ agglutinin (WGA)-Alexa Fluor® 594 conjugate from Invitrogen; 4',6-
diamidino-2-phenylindole (DAPI) and Vecstashield from Vector Laboratories, Inc. 
Polyethylene tubes were purchased from Smiths Medical International Ltd.; syringes and needles 
from Henke-Sass Wolf; syringe pumps from Braintree Scientific, Inc.; tissue culture flasks from 
Orange Scientific; dialysis membrane (10,000 MWCO; Snake Skin® pleated dialysis tubing) from 
Thermo Fisher Scientific; well-plates and Transwell® cell culture inserts (transparent polyester 
membrane; 12-well plate format; 0.4 µm pore size) from Corning; black well plates from Greiner 
Bio-One; plastic tissue culture coverslips (13 mm) from Sarstedt; carbon adhesive tape from Ted 
Pella, Inc.; coverslips from VWR.  
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The microfluidic device was kindly provided by Dr. Hélder Santos (Division of Pharmaceutical 
Technology, Faculty of Pharmacy, University of Helsinki, Finland).  
3.2 Conventional development of poly(lactic-co-glycolic acid) 
nanoparticles  
Considering the nanoprecipitation technique, PLGA (20 mg) and EFV, in a drug/polymer ratio 
(DP) of 2.5, 5, 10 or 15 %, were dissolved in 1 mL of organic solvent (20 mg/mL of PLGA in organic 
solvent), acetone or DMSO, and directly injected with a needle (25G) into 20 mL of the surfactant 
solution, 1/2 % of TWEEN®-80 or 1/2 % of PVA in deionized water. Then, the solution was left under 
mechanical stirring for 3 h, at 200 rpm and room temperature, to ensure organic solvent diffusion. 
For the modified nanoprecipitation technique, PLGA (80 mg) and EFV, in a DP of 15 %, were 
dissolved in 2 mL of organic solvent (40 mg/mL of PLGA in organic solvent), DMSO, and homogenized 
with 4 mL of the surfactant solution, 2 % of TWEEN®-80 in deionized water, by sonication (Sonics & 
Materials, Inc.) for 90 s at 70 % intensity. The resulting product was promptly poured in 7.5 mL of 
the surfactant solution, and kept under magnetic stirring for 4 h, at 300 rpm and room temperature, 
to ensure organic solvent diffusion. 
Empty NPs (i.e., without EFV) for both techniques were also prepared using the same procedure 
but skipping the addition of EFV. 
After production, NPs were washed three times with ultrapure water (ELGA system) and 
recovered by centrifugation (Beckman Avanti, JA2550 rotor, Beckman Instruments Inc.) or 
ultrafiltration using Amicon Ultra-15 Centrifugal Filter units (Millipore) with a molecular weight 
cutoff (MWCO) of 100 kDa. To better resuspend the formulation, if needed, samples were treated 
with glycerol or submitted to sonication (Sonics & Materials, Inc.) for 30 s at 30 % intensity. 
3.3 Microfluidic development of poly(lactic-co-glycolic acid) 
nanoparticles  
The microfluidic device was assembled by gathering borosilicate glass capillaries on a glass 
slide, as previously described [209, 220, 221]. Briefly, the chip was composed of two types of 
capillaries, for which the outer diameter of the cylindrical tapered capillary fitted the inner 
dimensions of the square capillary. One end of the cylindrical capillary (World Precision 
Instruments, Inc.), comprising an inner and outer diameters of around 580 and 1000 μm, 
respectively, was tapered using a micropipette puller (P-97, Sutter Instrument Co.) to a diameter of 
20 μm; then, this diameter was enlarged to around 80 μm using a microforge (P-97, Sutter 
Instrument Co.). This cylindrical tapered capillary was placed into the square capillary, which had 
an inner dimension of around 1000 μm (Vitrocom), and coaxially aligned. A transparent epoxy resin 
(5 minute ® Epoxi, Devcon) was used to fix the capillaries.  
The inner and outer fluids were injected separately into the chip through polyethylene tubes 
attached to syringes at constant flow rates controlled by syringe pumps. 
The dispersed and continuous phases were poured into distinct syringes to be separately 
injected in the microfluidic device as the inner and outer fluid, respectively. Two fluids geometries 
were induced, namely the co-flow and flow-focusing. The dispersed phase consisted on a 20 mg/mL 
and 40 mg/mL mixture of PLGA in organic solvent, DMSO, for the co-flow and flow-focusing 
geometry, respectively, and a quantity of EFV corresponding to a DP of 15 %. The continuous phase 
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consisted on a surfactant solution, 2 % of TWEEN®-80 in deionized water, for both geometries. The 
particles were collected in plastic tubes containing 500 µL of a solution with the same composition 
of the continuous phase, in order to facilitate their deposition and consolidation. In the co-flow 
geometry, the inner and outer fluids were pumped into the microfluidic device at 2500 and 3750 
µL/min, respectively. In the flow-focusing geometry, the inner and outer fluids were pumped into 
the microfluidic device at 1000 and 2500 µL/min, respectively. The production of NPs by 
microfluidics was run until reach a final volume of around 11.5 mL for the flow-focusing geometry 
and 20 mL for the co-flow geometry. Then, NPs suspensions were left overnight for solvent diffusion 
to occur (without magnetic stirring) and recovered by ultrafiltration. 
Empty NPs (i.e., without EFV) for both geometries were also prepared using the same procedure 
but skipping the addition of EFV. 
3.4 Characterization of nanoparticles 
3.4.1 Mean particle size, size distribution and surface charge 
Nanoparticles were characterized for their average size (Z-average) and polydispersity index 
(PDI) by dynamic light scattering (DLS), and zeta-potential (-potential) through laser Doppler 
anemometry (LDA), using a Malvern Zetasizer Nano ZS instrument.  
For these measurements, samples were diluted in an ionic solution of 10 mM sodium chloride. 
 
3.4.2 Drug association efficiency and drug loading  
To determine the association efficiency (AE) and drug loading (DL) of the developed 
nanosystems, the amount of EFV associated to the nanoparticles was indirectly estimated. This 
calculation was made by the difference between the total amount of EFV used to prepare the 
systems and the amount of EFV that remained in the aqueous phase, after nanoparticles isolation by 
ultrafiltration, according to Equations 3.1 and 3.2 [222]. 
 
                                    AE (%) =                            (3.1) 
 
                                   DL (%) =                             (3.2) 
 
The amount of EFV was determined using a high-performance liquid chromatography (HPLC) 
method previously established [223]. Briefly, the quantification was performed by reversed-phase 
HPLC with ultraviolet detection using a Merck-Hitachi LaChrom® HPLC system (Merck, NJ). A 
Symmetry C8 column (5 µm, 4.6×250 mm; Waters, Milford, MA) with LiChrospher 100 RP-18 guard 
column (Merck) was used as stationary phase. Chromatographic runs were performed using an 
isocratic method and the mobile phase used was acetonitrile:acetate buffer 10 mM (57:43), pH 4.0, 
at a flow rate of 1 mL/min. Samples injection volume was 10 µL and the detection was at 247 nm. 
The method was linear in the range of 1-50 µg/mL. 
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3.4.3 Morphology and chemical screening 
The morphological features of NPs were analyzed by transmission electron microscopy (TEM) 
with a JEOL JEM 1400 (JEOL Ltd.) microscope at an accelerating voltage of 120 kV. The energy-
dispersive X-ray spectra (EDS) were collected for chemical analysis. Images were digitally recorded 
using a Gatan SC 1100 ORIUS CCD camera (Warrendale). 
Samples were prepared by dropping 10 µL of NPs suspension onto a 300-mesh nickel grid. All 
samples were stained with uranyl acetate. Nanoparticles resulting from the microfluidic method of 
production were prior diluted ten times in water.  
3.5 Microfluidic method: scaling experiment 
Besides the above mentioned final volume of around 20 mL (standard scale), the production of 
EFV-loaded NPs using microfluidics by the co-flow geometry was also run until a final volume of 2 
mL (scale-down) and 200 mL (scale-up). The settings and methodology used were the same 
described in Section 3.3, and the results for the scale-down and scale-up were, a posteriori, 
compared with the ones obtained for the standard scale.  
3.6 In vitro release test 
To ensure that the release assay would be performed in sink conditions, the solubility of EFV in 
0.2 % of poloxamer in phosphate buffered saline (PBS) solution, pH = 7.4, was determined. Briefly, 
an excess amount of EFV (5 mg) was added to 3 mL of 0.2 % of poloxamer in PBS  
(to prepare a saturated solution), and placed for 15 min and 24 h in an orbital shaker incubator at 
100 rpm and 37 ºC (IKA). Subsequently, the suspension was centrifuged at 10,000 g (Beckman 
Avanti, JA2550 rotor, Beckman Instruments Inc.) for 15 min, and EFV from supernatants was 
quantified through HPLC analysis. 
For the release test, specifically, EFV loaded NPs (corresponding to 315 µg of drug) were added 
to 6 mL of 0.2 % of poloxamer in PBS solution, pH = 7.4, and then placed into an orbital shaker 
incubator, at 100 rpm and 37 ºC, during 24 h. Aliquots of 500 µL were collected at specific time 
points (0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 7, 9, 23, and 24 h) during the assay, and the 
withdrawn volume was replaced with pre-heated 0.2 % of poloxamer in PBS solution.  All the 
collected aliquots were centrifuged at 10,000 g for 15 min and the supernatant was used for HPLC 
analysis, in order to quantify the EFV released from NPs over time.  
3.7 Nanoparticles labeling  
The same protocol mentioned to produce EFV-loaded NPs by microfluidics and using the co-flow 
geometry was applied to obtain fluorescent NPs by encapsulating 6-C instead of the drug (in a 6-
C/polymer ratio of 0.1 %). Following the same procedure applied to evaluate EFV-loaded NPs, 6-C 
loaded NPs were analyzed for their Z-average, PDI, ζ-potential. The AE and release profile of these 
NPs were also accessed, where 6-C was quantified through fluorescence (ex. 460 nm, em. 510 nm) 
using a plate reader (Synergy Mx, Biotek). 
Previously to the release study, and ensuring that the assay would be performed in sink 
conditions, the solubility of 6-C in 0.1 % of TWEEN®-80 in PBS (pH = 7.4) was determined by 
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preparing a saturated solution. Briefly, an excess amount of 6-C (1 mg) was added to 5 mL of 0.1 % 
of TWEEN®-80 in PBS, and placed for 24 h in an orbital shaker incubator at 100 rpm and 37 ºC. 
Subsequently, the suspension was centrifuged at 10,000 g for 15 min, and the fluorescence of the 
supernatants was read in a plate reader.  
The release assay was performed with a dialysis membrane. 6-C loaded NPs (corresponding to 1 
mg of 6-C) were located inside the dialysis membrane, which was well closed at both extremities. 
The membrane was placed inside a beaker with 4 L of 0.1 % of TWEEN®-80 in PBS (pH = 7.4), with 
constant stirring (100 rpm) at 37 ºC. Samples of 1 mL were taken at time points of 0.5, 1, 2, 3, 4, 5 
and 24 h, and their fluorescence was then quantified in a plate reader.  
3.8 Nanoparticles functionalization and characterization 
3.8.1 Functionalization process 
The carbodiimide chemistry, or EDC/NHS coupling chemistry, was used to perform the covalent 
conjugation between the amine groups of a 12-amino acids peptide-binding transferrin receptor to 
the carboxyl group of NPs. This protocol was adapted from others previously described [209, 224].  
Briefly, 1 mg of NPs was dispersed in 1 mL MES solution (10 mM; pH = 5.5) containing 3.14 μL of 
EDC (17 mM) and NHS (1.2 mg). The pH was adjusted to 5.5, and the mixture was stirred (300 rpm) 
for 45 min at room temperature in the dark. Then, the product was concentrated until the minimum 
possible volume by ultrafiltration, in order to remove the maximum amount of EDC and NHS, and 
ressuspended again in 1 mL MES solution (10 mM) at pH = 5.5. Since carboxyl groups of NPs were 
already activated, the peptide was added in a molar ratio of 1:10 in relation to PLGA. Afterwards, 
the mixture was kept stirring (300 rpm) at room temperature for 3.5 h in the dark. Finally, NPs were 
collected by ultrafiltration and characterized as previously mentioned (Z-average, PDI, and -
potential). 
 
3.8.2 Bradford assay  
The Bradford assay was used to indirectly quantify the amount of conjugated peptide to NPs, by 
measuring the free peptide in the supernatant resulting from the ultrafiltration after the 
functionalization process. 
Briefly, 150 µL of Coomassie Reagent were added to the same volume of each standard or 
sample in a 96-well plate, and shaken during 30 seconds. Then, the plate was incubated for 10 
minutes at room temperature, and the absorbance was measured at 595 nm in a plate reader. The 
results were simultaneously compared with a standard curve of BSA and the same peptide used for 
NPs functionalization, in concentrations ranging from 0 to 25 µg/mL. The AE of the peptide to the 
NPs was calculated according to Equation 3.3.  
 
                                 AE (%) =                      (3.3) 
 
3.8.3 Nuclear magnetic resonance analysis 
To confirm the presence of the peptide in the formulation of functionalized NPs, proton nuclear 
magnetic resonance (1H NMR) spectroscopic analysis was used for the detection of differences on 
spectra from non-functionalized and functionalized particles. Non-functionalized and functionalized 
empty PLGA NPs, as well as commercial PLGA used in the production process of NPs, were dissolved 
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(3 mg) in DMSO and placed on appropriate nuclear magnetic resonance tubes. The analysis were 
performed at room temperature on a Brüker AMX 300 spectrometer operating at 400.13 MHz, with 
every chemical shift value (δ; ppm) expressed relatively to tetramethylsilane (TMS) as an internal 
reference. 
3.9 Cell culturing 
Both hCMEC/D3 and ND7/23 were grown in tissue culture flasks (passage 38–50 and 11-21, 
respectively).  
The hCMEC/D3 cell line was maintained in EBM-2 supplemented with FBS (5 %, v/v), penicillin-
streotomycin (1 %, v/v), hydrocortisone (1.4 μM), ascorbic acid (5 μg/mL), chemically defined lipid 
concentrate (1/100, v/v), HEPES (10 mM) and bFGF (1 ng/mL). This last supplement was added 
extemporaneously in the culture medium.  
The ND7/23 cell line was maintained in DMEM supplemented with FBS (10 %, v/v) and penicillin-
streotomycin (1 %, v/v).  
The cell cultures were kept in an incubator (CellCulture CO2 incubator, ESCO) at 37 ºC with 5 % 
CO2, in a water saturated atmosphere. Cell culture medium was changed every 2–3 days. 
3.10 Nanoparticles-associated metabolic viability assay 
The samples toxicity was assessed in the hCMEC/D3 and ND7/23 cell lines using the MTT 
metabolic viability assay.  
A preliminary study was made to find the optimal cellular density of ND7/23 cell line. Cells were 
seeded in a 96-well plate in a concentration of 0.001, 0.005, 0.010, 0.015, 0.020, 0.040, 0.060, 
0.080 and 0.100  106 cells/mL in supplemented DMEM. Then, MTT test was done according to 
manufacters’ instructions, but cells were only incubated with medium, in order to further evaluate 
the resulting absorbances. The cellular density that proved to be the most appropriate one for the 
ND7/23 cell line was used for the seeding of these cells (0.015  106 cells/mL; 200 µL). For the 
hCMEC/D3 cell line, 200 µL of cells were seeded in a 96-well plate (0.04  106 cells/mL) in 
supplemented EBM-2. This cellular density was already described in a previous work [224].  
After the seeding, cells were incubated during 24 h and then medium was removed and cells 
were washed with 200 μL of PBS. Thereupon, cells were incubated with free EFV, empty NPs, 
functionalized empty NPs, EFV-loaded NPs and functionalized EFV-loaded NPs, in concentrations of 
100, 10, 1, 0.1, and 0.01 µM (in medium) determined in relation to the drug, for 24 h. Afterwards, 
solutions were discarded, cells were washed with 200 μL of PBS and then treated with 200 μL of 
MTT solution (0.5 mg/mL, in medium) per well, during 4 h in the dark. Formazan crystals, resulting 
from the reduction of MTT by viable cells, were solubilized with 200 μL of DMSO, under a 20 min 
slight shake, at 100 rpm and room temperature. Finally, absorbance was measured at 590 and 630 
nm using a plate reader.  
A negative control (NC), consisting on cells incubated with 1 % of Triton X-100 in medium 
solution, which has a detergent effect capable of disrupt cells (0 % of metabolic activity), and a 
positive control (PC), consisting on cells incubated only with medium (100 % of metabolic activity), 
were also prepared and treated similarly to the sample wells. Metabolic activity was expressed as a 
percentage compared to the controls according to the Equation 3.4. 
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                                        Metabolic activity (%) =                             (3.4) 
3.11 Nanoparticles hemocompatibility assay 
3.11.1 Quantification of hemolysis 
The assay related to the quantification of hemolysis resulted from an adaptation of the protocol 
previously described by Pinto et al. [225]. Red blood cells were isolated from buffy coats (obtained 
from Immunohemotherapy Service, S. João Hospital, Porto, Portugal). Briefly, 2 mL of the buffy 
coat content were centrifuged (Eppendorf 5810R) over density gradient with 2 mL of Histopaque-
1077 for 30 min at 400 g and room temperature, in accordance with the instructions of the 
manufacturer. After removal of the plasma upper layer, the lower layer containing red blood cells 
was washed three times with 8 mL of PBS (centrifugations for 30 min at 400 g and room 
temperature). Then, 100 µL of red blood cells in a concentration of 2  108 cells/mL were placed in 
eppendorf tubes. Next, 100 µL of free EFV, empty NPs, functionalized empty NPs, EFV-loaded NPs 
and functionalized EFV-loaded NPs were added to the tubes to obtain a final concentration of 50, 5, 
0.5, 0.05, and 0.005 µM in PBS (concentrations determined in relation to the drug). Eppendorf tubes 
were incubated for 3 h at 100 g and 37 ºC. Afterwards, the tubes were centrifuged (Eppendorf 
5417R) at 4000 rpm for 5 min to collect the supernatants, which were transferred (80 µL) to black 
polypropylene 96-well plates for absorbance reading, using a plate reader.  
The PC, consisting on cells incubated with 1 % of Triton X-100 in PBS (100 % hemolysis), and NC, 
consisting on cells incubated only with PBS (lysis negative control; 0 % hemolysis), were also 
prepared and treated similarly to the sample tubes.  
The hemoglobin value of the samples was calculated in accordance with Equation 3.5.  
 
                     Hemoglobin value of sample (mg/dL) = ,               (3.5) 
 
where A380 is the absorbance value at 380 nm, A415 is the absorbance value at 415 nm, A450 is the 
absorbance value at 450 nm, Df is the dilution factor (that was 35), and E is the molar absorptivity 
of oxyhemoglobin at 415 nm (that is 79.46). The absorbance value at 415 nm corresponds to the 
Soret band absorption of hemoglobin, and the absorbance values at 380 and 450 nm correspond to 
the absorption of uroporphyrin, which falls under the same wavelength range.  
Afterwards, the hemolytic potential of the samples was calculated in accordance with Equation 
3.6. 
                                    Hemolysis (%) =                                        (3.6) 
 
The osmolarity of the formulations incubated with red blood cells were also determined at room 
temperature using a Micro-Osmometer M3320 (Advanced Instruments, Inc.). 
 
3.11.2 Morphology of red blood cells 
The assay related to the assessment of cell membrane integrity and morphology of red blood 
cells resulted from an adaptation of the protocol previously described by Shahbazi et al. [226] and 
was based on scanning electron microscopy (SEM) imaging. Briefly, and after the isolation of red 
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blood cells from buffy coats as described for the quantification of hemolysis, 1 mL of red blood cells 
in a concentration of 4  105 cells/mL in HBSS were seeded in 6-well plates containing plastic tissue 
culture coverslips.  Then, NPs were added in 1 mL of HBSS to reach a final concentration of 50 µM. 
The plates were placed in an orbital shaker incubator for 3 h at 37 ºC and 100 rpm.  
The NC, consisting on cells incubated only with HBSS (lysis negative control; 0 % hemolysis), was 
also prepared and treated similarly to the sample wells.  
The cells were then fixed in 2.5 % glutaraldehyde in sodium cacodylate buffer (pH = 7.4) for 1 h, 
and dehydrated in increasing concentrations of 50, 70, and 100 % of ethanol for 5, 20, and 15 min, 
respectively. Finally, the coverslips were removed from wells, mounted on SEM supports using 
double sided carbon adhesive tape, and observed under SEM (FEI Quanta 400F). Before the SEM 
acquisition, samples were coated with gold/platinum under vacuum for 90 s, with a 15 mA current. 
An electron beam intensity of 10 kV and magnification ranging from 1000 to 15500 times were used. 
3.12 Evaluation of cell-nanoparticle interaction 
The quantification of the nanoparticles associated to hCMEC/D3 cells was evaluated using flow 
cytometry (fluorescence-activated cell sorting, FACS).  
Cells were seeded in 6-well plates (0.28  106 cells per well in 1.5 mL of supplemented EBM-2) 
and were allowed to attach overnight. The cells were washed twice with pre-warmed 2 mL PBS pH 
7.4, and then 1 mL of 6-C-loaded NPs in EBM-2, corresponding to 80 μg per well, were added to 
each well and incubated for 1 and 3 h at 37 ºC. After incubation, cells were washed twice with PBS 
and detached with versene. The cells were then washed twice with PBS and collected through 
centrifugation (Eppendorf 5810R) at 1300 rpm during 8 min. Finally, cells were ressuspended in 500 
µL of PBS and placed in cytometer tubes. 
The quantification was done using a FACS CANTO II cytometer (BD Biosciences), equipped with 
three laser with excitation of 405, 488 and 633 nm, where NPs were detected through the 488 nm 
channel. The results were analyzed using the software FlowJo vX.0.7.  
3.13 Blood-brain barrier in vitro model 
The guidelines to set up the BBB in vitro model used in this work were already reported in 
previous works [227, 228]. 
Briefly, to develop the BBB in vitro model, 2.5  104 cells/cm2 of hCMEC/D3 cells (500 µL; 
supplemented EBM-2) were seeded on 12-Transwell® cell culture inserts. Previously to the seeding, 
the inserts were coated with 90 μL of a 50 μg/mL rat tail collagen type I in acetic acid solution (0.02 
M) for 1 h, at 37°C, and then washed twice with PBS. The basolateral side of the wells were filled 
with 1.5 mL of supplemented EBM-2.  
The system was maintained in the incubator at 37 ºC with 5 % CO2 during 8 days, and medium 
was changed every 2 days. The hCMEC/D3 cells monolayer became confluent at the 8th day, which 
was the day appropriate to perform the permeability study.  
The integrity of the cell monolayer was checked every 2 days by monitoring the transendothelial 
electric resistance (TEER) using an endothelial Volt–Ohm meter (Millicell® ER S-2; Millipore). The 
resistance value of an empty filter was subtracted from each measurement. 
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3.14 Evaluation of the blood-brain barrier in vitro model integrity 
In order to evaluate the integrity of the BBB monoculture barrier, at culture day 8, the insert 
membranes presenting the hCMEC/D3 monolayer were stained and analyzed by confocal microscopy.  
Insert membranes were fixed with 4 % paraformaldehyde in PBS for 10 min at room 
temperature, and washed three times with HBSS. After removal of HBSS, cell membranes were 
stained with 500 µL of 5 µg/mL Alexa Fluor® 594 WGA (apical compartment) in the dark during 20 
min at room temperature. After, membranes were washed three times, 5 min each. Cell nuclei 
were then stained with 500 µL of 100 ng/mL DAPI (apical compartment) in the dark during 15 min at 
room temperature. After removal of DAPI, membranes were mounted on a glass slide in Vectashield 
and covered with a coverslip. The slides were observed using a confocal microscope (Leica 
Microsystems GmbH). 
3.15 Permeability study 
The permeability experiment across the cell monolayer (8th day of the BBB in vitro model) was 
performed in the apical-to-basolateral direction. After removing the cell culture medium, the 
basolateral compartment was filled with 1.5 mL of HBSS. Regarding the apical compartment, 500 μL 
of 10 µM of free EFV, EFV-loaded NPs, and functionalized EFV-loaded NPs diluted in HBSS were 
added (concentrations determined in relation to the drug). Then, the assay was conducted at 37 ºC 
using an orbital shaker incubator (100 rpm). At different time points (15, 30, 45, 60, 90, 120 and 
180 min), 200 µL samples were taken from the basolateral side, and the same volume of pre-heated 
HBSS was added to replace the withdrawn volume. At the last time point, 200 µL samples were also 
taken from the apical side in order to quantify the amount of EFV which did not permeate through 
the membrane, and cell monolayers were treated with 1 % of Triton X-100 in PBS, in order to disrupt 
cells and quantify the amount of EFV internalized by them. All samples were used for HPLC analysis, 
in order to quantify EFV. 
The integrity of the cell monolayer was checked during the permeability experiment by 
monitoring the TEER.  
The permeability results were expressed in percentage of permeability and apparent 
permeability (Papp). Papp was calculated using Equation 3.7.  
                                                                                              (3.7)     
           
where C0 is the initial concentration in the apical compartment of the insert, which was 3.16 
μg/mL, A is the surface area of the insert (0.9 cm2), Δt is the time during which experiment 
occurred in seconds (10800 seconds), and ΔQ is the amount of drug detected in the basolateral 
compartment in μg. 
3.16 Statistical analysis 
All the results were represented as mean ± standard deviation from a minimum of three 
independent experiments. Statistical analysis was performed by one-way analysis of variance 
(ANOVA) followed by a post hoc test (Tukey's honestly significant difference) to compare more than 
two groups. In case of comparison of two different groups, unpaired Student t-test was used.  
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Differences were considered significant at * p < 0.05, ** p < 0.01, or *** p < 0.001. All statistical 
analyses were performed with the software GraphPad Prism 5 (GraphPad Software Inc.).  
 
 
 
 
 
 
 35 
Chapter 4 
Results and Discussion 
4.1 Conventional production of nanoparticles 
Before moving forward to the microfluidics-based NPs production, some parameters had to be 
optimized for the conventional method, namely, the selection of the most appropriate recovering 
process after NPs synthesis, surfactant, organic solvent, and the introduction of possible attempts 
to improve the final characteristics of the nanosystems. The effect of each change on NPs 
properties was accessed by evaluating the Z-average, PDI, ζ-potential, AE and DL of the 
formulations. 
Firstly, the production of NPs was run by means of the regular protocol for the conventionally-
performed nanoprecipitation technique, using acetone and 2 % of TWEEN®-80 as the organic solvent 
and surfactant solution, respectively. Basically, the organic phase was added to the continuous 
phase, and this step was performed with a needle positioned directly into the core of the external 
phase (continuous) to prevent the occurrence of a superficial polymeric film [229]. The process is 
schematized in the Figure 4.1. The produced NPs were then collected by centrifugation using 
different speeds and times. Speeds of 10,000, 15,000, 20,000, 23,000, and 27,000 g, and 
centrifugation times of 15, 20, 30, 40, and 45 min were tested. NPs could not be ressuspended after 
ultracentrifugation, even trying slight speeds during a short period of time. Thereupon, in order to 
facilitate the resuspension of the formulation, the pellet was sonicated for 30 s at 30 % intensity. 
Still, the pellet was not perfectly ressuspended. As another strategy to facilitate the resuspension 
of the formulation, a glycerol bed in the bottom of the centrifugation tube was used. Once again, 
irreversible caking of the NPs occurred. Due to the impossibility of using ultracentrifugation while 
maintaining the formulation in viable conditions, the ultrafiltration was adopted to perform the 
recovering process in the next experiments.   
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Figure 4.1 – Nanoprecipitation technique to produce NPs. The dispersed phase was added to the continuous 
phase, and then the product was stirred to promote organic solvent diffusion. 
 
When performing the conventional nanoprecipitation technique with acetone and 2 % of 
TWEEN®-80, empty NPs with an approximately Z-average, PDI, and ζ-potential of 173 nm, 0.1, and -
29 mV, respectively, were obtained (Table 4.1). Generally, the mean size of NPs for brain-targeted 
drug delivery should be up to 200 nm to enable endocytosis by capillary cells [230], and thus the 
formulation demonstrated to be satisfactory in respect to this issue. The PDI is an important 
formulation parameter because it affects NPs transport properties, biological activity and 
therapeutic efficiency [231]. Values of PDI up to 0.3 are described to be related with homogeneous 
populations of particles. However, PDI values higher than 0.3 usually mean the presence of a non-
homogenous population and a presumable occurrence of NPs aggregation [232]. Herein, the 
formulation demonstrated to be homogenous. Also, the negative surface charge of the obtained NPs 
was expected, being consistent with the work of Stolnik et al. [233] who attributed this feature to 
the end carboxyl groups of PLGA. Then, EFV-loaded NPs were produced with the same composition, 
and different percentages of DP, namely, 2.5, 5, 10, and 15 %, were tested. The results are shown 
in Table 4.1. Although no relevant differences were observed in other parameters, the DP of 15 % 
was associated with the higher values of AE and DL. However, a maximum AE and DL of only 51 and 
8 %, respectively, were obtained.  Since these results implied a big loss of drug, a different 
percentage of TWEEN®-80, 1 %, was tested on the production process, while maintaining NPs 
composition and the DP of 15 %. Besides other differences perceived in NPs features, there was a 
significant decrease in AE (** p < 0.01) and DL (* p < 0.05), and therefore no improvements were 
seen by replacing 2 % of TWEEN®-80 (Table 4.1). For this reason, another surfactant solution, PVA, 
at two different concentrations of 1 and 2 %, was also tested, while maintaining again NPs 
composition and a DP of 15 %. Herein, both formulations containing PVA presented similar 
properties (Table 4.1). Apart from the significant increase in size (** p < 0.01) and charge (*** p < 
0.001) regarding the formulation with 2 % of TWEEN®-80, an outstanding increase in AE and DL (*** p 
< 0.001) was also noted. However, this increase raised some doubts and the possibility of the 
interference of the collecting process of NPs, consisting on ultrafiltration, on these values was 
investigated. Since it was possible to observe a PVA mass attached to the filter, it was verified 
whether that could lead to retention of the non-associated drug, hence avoiding its detection on 
the supernatant afterwards. By ultrafiltrating a solution of free EFV in 2 % of PVA or TWEEN®-80, it 
was possible to observe that, in the formulations containing PVA, not all the drug was present on 
the supernatant in the end so, the emergence of false positive results related to this surfactant was 
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confirmed. Oppositely, the TWEEN®-80 demonstrated to be a reliable surfactant and thus it did not 
cause the previously described effect. Ultimately, and returning to the beginning, the next 
experiments were performed using 2 % of TWEEN®-80 as the surfactant solution and a DP of 15 %. 
 
Table 4.1 – Optimization of the conventional process of fabrication of NPs. Results are presented as mean ± SD 
(n = 3).  
Organic 
solvent 
Surfactant  
(%) 
DP  
(%) 
Z-average 
(nm) 
PDI 
ζ-Potential 
(mV) 
AE 
(%) 
DL 
(%) 
Acetone 
2 % 
TWEEN®-80 
- 
173.4  
± 2.7 
 
0.110  
± 0.010 
 
-28.3  
± 3.3 
 
- - 
2.5 
176.5  
± 2.5 
 
0.081  
± 0.012 
 
-23.8  
± 1.3 
 
34.4  
± 9.7 
 
0.9  
± 0.2  
***  
5 
178.1  
± 2.3 
 
0.079  
± 0.011 
 
-24.1  
± 2.1 
 
37.2  
± 6.0 
 
1.8  
± 0.3  
*** 
10 
177.4  
± 2.2 
 
0.084  
± 0.011 
 
-26.2  
± 1.9 
 
37.2  
± 3.3 
 
3.6  
± 0.3  
** 
15 
180.2  
± 4.7 
 
0.089  
± 0.015 
 
-22.0  
± 1.6 
 
40.9  
± 6.7 
 
5.8  
± 0.9 
 
1 % 
TWEEN®-80 
15 
152.4  
± 2.5  
** 
0.077  
± 0.014 
 
- 26.1  
± 1.7  
* 
26.4  
± 2.5 
 ** 
4.0  
± 0.4  
* 
1 % 
PVA 
207.9  
± 10.9  
** 
0.099  
± 0.036 
 
- 0.7  
± 0.1  
*** 
98.5  
± 0.2  
*** 
14.6  
± 0.0  
*** 
2 % 
PVA 
204.3  
± 1.3  
** 
0.087  
± 0.012 
 
- 0.6  
± 0.0  
*** 
97.3 
± 0.5 
 *** 
14.4  
± 0.1  
*** 
 
DP: drug/polymer ratio; Z-average: average size; PDI: polydispersity index; ζ-Potential: zeta-potential; AE: 
association efficiency; DL: drug loading; PVA: poly(vinyl alcohol). 
* p < 0.05; ** p < 0.01; *** p < 0.001 (comparison done in relation to NPs produced with 2 % of TWEEN®-80 and a 
DP of 15 %). 
 
At this point of the work, some feedback about the capabilities of the microfluidic system, 
which will be explored in detail on the next section, started to being received. Since the main goal 
was to compare the final formulations obtained by the conventional with the microfluidic method, 
the reagents and respective concentrations were maintained between both methods. So, as will be 
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described later, there was a need to exchange the organic solvent involved on the production 
process of NPs, from acetone to DMSO. All the other formulation components and methodology were 
kept. The change of the solvent slightly affected the final properties of NPs produced by the 
conventionally-performed method, which will be discussed later on this chapter (Table 4.2; Section 
4.3).  
Finally, besides the regular nanoprecipitation, a new methodology based on a modified 
nanoprecipitation technique, including an extra sonication step, was introduced. This modified 
technique consisted of adding the dispersed phase to a small volume of continuous phase, followed 
by immediate sonication (first dispersion) and dilution of the resulting product in a bigger volume of 
continuous phase (second dispersion). R. Kulterer et al. [234] already described the influence of 
sonication on nanoprecipitation, concluding that it promotes the prompt disruption of the dispersed 
phase into small drops, right after reaching the continuous phase, and speeds up the intermixing 
process of the two phases. The first dispersion of the oil phase in a small quantity of surfactant 
solution with the sonication probe may promote a faster second dispersion, hence allowing a faster 
diffusion of that phase through the continuous one. In the regular nanoprecipitation, the single 
dispersion begins on the perimeter around the needle, and then it spreads to the periphery through 
a centrifugal gradient, which may lead to a slow diffusion of the dispersed phase through the 
continuous one. The aim inherent to this methodology was to obtain NPs with smaller dimensions 
when using the modified nanoprecipitation technique, since they are directly associated with a 
faster diffusion during the formation process of the particles. Moreover, the introduction of a 
modified nanoprecipitation methodology was important to verify if the microfluidic method would 
be able to surmount this improved version of the technique. Therefore, the results related to NPs 
properties will be discussed and compared between both methods later on (Table 4.2; Section 4.3).  
 
 
 
Figure 4.2 – Modified nanoprecipitation technique to produce NPs. This process involved two different 
dispersions of the organic phase in the aqueous one. 
4.2 Nanoparticles production by microfluidics 
The microfluidic platform was composed of a square capillary and a cylindrical tapered 
capillary. The outer diameter of the cylindrical tapered capillary fit the inner dimensions of the 
square capillary, facilitating the alignment of their axes.  
The geometry of the microfluidic systems are designed to provide unique flow patterns. Herein, 
the co-flow and flow-focusing geometries were adopted to perform the nanoprecipitation technique 
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in the microfluidic chip. In order to compare the differences in NPs properties between the 
microfluidic and conventional methodology, the microfluidics-related results of the co-flow and 
flow-focusing geometries were compared with the conventional method-related results of the 
nanoprecipitation and modified nanoprecipitation techniques, respectively. Therefore, the 
microfluidic production was run until reach a final volume equal as the one obtained when 
performing the techniques by conventional methods, which is around 20 mL for the co-flow 
geometry, and 11.5 mL for the flow-focusing geometry. Moreover, PLGA and EFV in DMSO, and 
TWEEN®-80 concentrations used to perform the conventional method were exactly replicated in the 
microfluidic method. 
In the co-flow geometry (Figure 4.3), the dispersed phase (inner fluid) flowed inside the inner 
cylindrical capillary, while the continuous phase (outer fluid) flowed between the inner and outer 
cylindrical capillaries in the same direction, resulting in the formation of the NPs. The two fluids co-
flowed in parallel directions, and underwent mixing by well-defined diffusion after met each other.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 – Co-flow geometry in the microfluidic platform. 
 
In the flow-focusing geometry (Figure 4.4), the dispersed phase (inner fluid) was injected into 
the left extreme of the square capillary, whereas the continuous phase (outer fluid) was injected in 
the opposite direction through the interstices between the right extreme of the square capillary and 
the cylindrical capillary. The two fluids flowed oppositely, and underwent mixing by well-defined 
diffusion after met each other. Moreover, the stream was forced to pass through the tapered tip of 
the cylindrical capillary and consequently narrow its shape. This resulted in the formation of the 
NPs. 
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Figure 4.4 – Flow-focusing geometry in the microfluidic platform. 
 
Different types of preliminary assays were made to optimize the process conditions and find the 
most appropriate setup to produce NPs by microfluidics. In terms of organic solvents, the production 
was initiated using acetone, as described in Section 4.1. However, it caused several issues related 
to clogging of the microfluidic chip, especially for the concentration of 40 mg/mL of PLGA, used as 
the inner fluid when adopting the flow-focusing geometry. Therefore, there was a need to change 
the organic solvent, and thus DMSO was selected to proceed with NPs development (the 
methodology was uniformed in order to use DMSO in every process of NPs production). DMSO 
prevented the emergence of clogging phenomena in the microfluidic chip, and, in addition, it 
belongs to solvents Class III, which is known by its low toxic potential, being widely used in the 
pharmaceutical field [235]. Afterwards, the effect of different inner and outer fluid flow rates on 
NPs size, PDI and ζ-potential was accessed for each fluids geometry adopted. The main goals were 
to achieve a size of NPs similar or lower than the ones obtained by the conventional method, the 
lowest possible value for PDI, and a ζ-potential of NPs similar to the ones obtained by the 
conventional method. Besides NPs properties, the time necessary to complete one batch of NPs was 
also taken into account. The effect of each combination of inner and outer fluid flow rate was 
translated in different values of Z-average, PDI and ζ-potential. Firstly, it is important to mention 
that, for both geometries and for all fluids flow rates tested, the ζ-potential did not vary 
significantly. Regarding the co-flow geometry, in test a), different outer fluid flow rates with a 
fixed inner fluid flow rate were experienced (Figure 4.5a). The flow rates of 20 µL/min and 50 
µL/min for the inner and outer fluid, respectively, were considered the most adequate combination 
after this test, due to the lowest value obtained of PDI. In test b), the flow rates ratio derived from 
20 µL/min (inner fluid) and 50 µL/min (outer fluid) was fixed, and then the flow rates were changed 
maintaining this proportion (Figure 4.5b). Herein, the flow rates of 1500 µL/min and 3750 µL/min 
for the inner and outer fluid, respectively, were considered the most adequate combination; 
besides this combination did not present the lower NPs size, it was verified that these flow rates 
were associated with the lowest value of PDI. In test c), the outer fluid flow rate of 3750 µL/min 
was fixed, and the inner fluid flow rate was altered (Figure 4.5c). The flow rates of 2500 µL/min 
and 3750 µL/min were selected for the inner and outer fluid, respectively, because it seemed that, 
from these values on, Z-average and PDI reached a minimum limit. Thus, for the co-flow geometry, 
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the inner and outer fluid flow rates were definitely stipulated as 2500 and 3750 µL/min, 
respectively. Regarding the flow-focusing geometry, in test a), the outer fluid flow rate was 
changed, while maintaining a fixed inner fluid flow rate (Figure 4.6a). The flow rates of 20 µL/min 
and 800 µL/min for the inner and outer fluid, respectively, were considered the most adequate 
combination, due to the acceptable low value of Z-average and PDI, in this context; moreover, 
these highest values of flow rates meant the faster production of NPs. In test b), the flow rates 
ratio derived from 20 µL/min (inner fluid) and 800 µL/min (outer fluid) was fixed, and then the flow 
rates were proportionally changed (Figure 4.6b). Herein, the flow rates of 62.5 µL/min and 2500 
µL/min for the inner and outer fluid, respectively, were considered the most adequate 
combination, due to the lowest value of PDI and the acceptable value of Z-average. In test c), the 
outer fluid flow rate of 2500 µL/min was fixed, and the inner fluid flow rate was altered (Figure 
4.6c). The flow rates of 1000 µL/min and 2500 µL/min were selected for the inner and outer fluid, 
respectively, because a low value of PDI and a satisfactory value of Z-average were reached. Thus, 
for the flow-focusing geometry, the inner and outer fluid flow rates were definitely stipulated as 
1000 and 2500 µL/min, respectively. 
Later on, the NPs resulting from these selected arrangements of fluids flow rates were analyzed 
in terms of their properties (Table 4.2; Section 4.3).  
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Figure 4.5 – Optimization of the flow rates in the microfluidic chip for the inner and outer fluid during the 
performance of the co-flow geometry. 
Inner fluid flow rate:outer fluid flow rate (µL/min) 
Inner fluid flow rate:outer fluid flow rate (µL/min) 
Inner fluid flow rate:outer fluid flow rate (µL/min) 
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a)    
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
c) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 – Optimization of the flow rates in the microfluidic chip for the inner and outer fluid during the 
performance of the flow-focusing geometry.  
Inner fluid flow rate:outer fluid flow rate (µL/min) 
Inner fluid flow rate:outer fluid flow rate (µL/min) 
Inner fluid flow rate:outer fluid flow rate (µL/min) 
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4.3 Conventional and microfluidic method: comparison of 
nanoparticles properties  
After production, EFV-loaded NPs formulations were evaluated for Z-average, PDI, ζ-potential, 
AE, DL, morphology, and chemical profile. As mentioned above, microfluidics-related results of the 
nanoprecipitation tecnhique performed through the co-flow and flow-focusing geometry were 
compared with the conventional bulk method-related results of the technique and modified 
technique, respectively.  
 
4.3.1 Average size, polydispersity index and surface charge  
The results for the evaluation of the obtained NPs in relation to their Z-average, PDI, and ζ-
potential were depicted in Table 4.2. 
All of the obtained formulations presented NPs which met the requirement of a Z-average under 
200 nm, which is important to accomplish the brain-targeted drug delivery [230], as mentioned 
above. For the nanoprecipitation technique (test 1), the size of NPs obtained by microfluidics 
(around 70 nm) was significantly lower (*** p < 0.001) compared to the conventional methodology 
(around 133 nm). Considering the modified nanoprecipitation technique (test 2), NPs size results 
were not significantly different between the two production methods. Furthermore, NPs produced 
by microfluidics using the co-flow geometry consisted on the only nanosystem which presented a Z-
average lower than 100 nm. It is well known that lower sizes of NPs enable longer blood half-time 
[236]. Moreover, Gao et al. injected polymeric drug-loaded NPs with sizes of 70, 170, 220 and 345 
nm into rats (at the same dose), and proved that NPs with a size smaller than 100 nm led to the 
highest drug level in the brain; the authors associated the size of 70 nm with an easier endocytosis 
of NPs by vascular endothelial cells of the BBB [237]. 
In relation to PDI of NPs, results were not significantly different between the different 
approaches (for both test 1 and 2). However, it is necessary to highlight that the microfluidic 
technology was able to provide PDI values as low as the ones obtained by the conventional 
methodology (around 0.1). This was expected since particles narrow size distribution is commonly 
associated with microfluidics [238].  
Regarding formulations ζ-potential, results demonstrated a significant increase in surface charge 
(**p < 0.001) when performing NPs production by microfluidics, instead of the conventional 
methodology. This may be explained by an increase in the quantity of TWEEN®-80 associated with 
the particles when they were produced using the microfluidic approach, hence retaining a less 
negative charge [239]. Still, all formulations presented a negative ζ-potential, which is due to the 
PLGA profile [233], as mentioned before. 
Empty and EFV-loaded NPs presented similar properties in relation to the mentioned physico-
chemical parameters.  
 
4.3.2 Association efficiency and drug loading 
In order to define the amount of drug associated to the NPs, the quantification of EFV was 
carried out by HPLC and indirectly calculated (Equations 3.1 and 3.2). New calibration curves were 
set in the beginning of every experiment to verify the feasibility of the method proposed to detect 
EFV. This curve was constructed based on standard solutions freshly prepared in acetonitrile, thus 
considering the mobile phase of the method and the solution in which the NPs were analyzed, as 
well. The calibration curve comprised a range of EFV concentrations from 1 μg/mL to 50 μg/mL, at 
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equally spaced intervals. In Figure 4.7 is possible to find a model for this curve. The obtained 
calibration curves always presented a coefficient of determination value (R2) between 0.990 and 
0.999, which demonstrated the feasibility of the method [240]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 – Standard curve calibration for EFV quantification using HPLC. 
 
The results for the evaluation of the obtained NPs in relation to AE and DL are depicted in Table 
4.2. 
Regarding the nanoprecipitation technique (test 1), microfluidics-associated AE was significantly 
higher (around 80 %; *** p < 0.001) compared to the conventional methodology, with a difference of 
around 50 %. Moreover, DL experienced a significant increase (*** p < 0.001) in microfluidics-
produced NPs (around 11 %) in comparison to the conventional method (around 3 %). Literature data 
attributed reduced drug loss to fewer steps involved in microfluidics-assisted NPs production 
compared to sequential conventional mixing of multiple phases [241]. The selected combination of 
inner and outer flow rate allowed matching drug flow with drops generation, thus contributing to a 
better drug entrapment. Liu et al. attributed AE and DL differences between the two methods to 
the fixed higher volume ratio between the continuous and dispersed phase in microfluidics, instead 
of a gradual increase in the ratio of these two phases during the conventional NPs synthesis process 
[212]. It is well known that changes in the ratio between the two phases affect drugs distribution in 
NPs matrix [242]. Moreover, it is probable that a slower solvent diffusion in microfluidics might 
promote less simultaneous drug migration out of the particles during the fabrication process, 
creating a coefficient which did not favor EFV presence in the continuous phase. This is in 
accordance with the work of Liu et al. [202], who referred that microfluidics reduces the movement 
of molecules from the dispersed to the continuous phase, hence promoting the effectiveness of drug 
entrapment. NPs formulations associated with low AE and DL values imply the administration of 
large amounts of non-therapeutic excipients to reach a clinically relevant drug dose which is 
associated with side effects emergence [243, 244]. These two parameters are of extreme 
importance when developing drug delivery nanosystems.  
Considering the modified nanoprecipitation technique (test 2), the obtained AE and DL were not 
significantly different between the two implemented methods, conventional and microfluidics; 
these results demonstrated that the microfluidic method is not able to improve these features in 
comparison to the conventional one. 
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Table 4.2 – Properties of NPs resulting from different approaches. In the test 1, NPs resulting from the 
conventionally-performed nanoprecipitation were compared with the ones resulting from microfluidics using 
the co-flow geometry. In the test 2, NPs resulting from the conventionally-performed modified 
nanoprecipitation were compared with the ones resulting from microfluidics using the flow-focusing geometry. 
Results are presented as mean ± SD (n = 3).  
Test 
Method/ technique  
or geometry 
NPs type 
Z-average 
(nm) 
PDI 
ζ-Potential 
(mV) 
AE 
(%) 
DL 
(%) 
1 
Conventional/ 
nanoprecipitation 
Empty 
134.0  
± 2.7  
 
0.092  
± 0.009 
 
-27.4  
± 3.1 
 
- - 
EFV-
loaded 
133.0  
± 3.6  
 
0.090  
± 0.010 
 
-28.0  
± 2.4 
 
32.7  
± 1.0 
  
3.2   
± 0.1 
 
Microfluidics/  
co-flow 
Empty 
70.9  
± 3.2  
*** 
0.085  
± 0.003 
 
-15.0  
± 1.6 
** 
- - 
EFV-
loaded 
72.8  
± 4.9  
*** 
0.086  
± 0.004 
 
-14.1  
± 2.3 
** 
80.7  
± 8.3  
*** 
10.8  
± 1.1 
*** 
2 
Conventional/  
modified 
nanoprecipitation 
Empty 
134.4  
± 3.9 
 
0.083  
± 0.008 
 
- 24.3  
± 1.9 
 
- - 
EFV-
loaded 
137.3  
± 6.6 
 
0.084  
± 0.006 
 
- 23.9  
± 1.6 
 
65.6  
± 2.5 
 
6.2   
± 0.2 
 
Microfluidics/  
flow-focusing 
Empty 
145.1  
± 3.0 
 
0.075  
± 0.012 
 
-14.8  
± 1.6 
** 
- - 
EFV-
loaded 
146.8  
± 4.8 
 
0.075  
± 0.010 
 
-15.0  
± 1.9 
** 
56.9  
± 2.0 
 
2.8   
± 0.1 
 
 
DP: drug/polymer ratio; Z-average: average size; PDI: polydispersity index; ζ-Potential: zeta-potential; AE: 
association efficiency; DL: drug loading; NP: nanoparticle; EFV: efavirenz. 
** p < 0.01; *** p < 0.001 (comparison done between the same NPs type inside each test group). 
 
In conclusion, the performance of the nanoprecipitation technique by microfluidics using the co-
flow geometry demonstrated to be indeed advantageous to develop EFV-loaded NPs. Besides 
providing comparable features of NPs to the ones obtained by the conventional methodology 
regarding PDI, and a smaller Z-average compared to the conventional procedure, the microfluidic 
method allowed significant better results of drug association efficiency and loading. Still, 
performing the nanoprecipitation technique by microfluidics using the flow-focusing geometry did 
not present any improvement in comparison to the conventional method. 
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The next stage of the work consisted on the evaluation of NPs morphology and chemical 
screening, comparing the outcomes of the conventionally-performed nanoprecipitation technique 
with the microfluidics-assisted nanoprecipitation using the co-flow geometry.   
 
4.3.3 Morphology and chemical screening  
The TEM analysis was performed for EFV-loaded PLGA NPs produced by nanoprecipitation using 
both conventional and microfluidic methods (co-flow geometry). The results are demonstrated in 
Figure 4.8.  
Data revealed round-shaped particles with relatively smooth surfaces. Moreover, no apparent 
morphological differences were found between NPs resulting from the two production methods.  
 
 
 
Figure 4.8 – TEM images of EFV-loaded PLGA NPs produced by the conventional and microfluidic method. From 
left to right, each column of images corresponds to a different magnification, namely, 50000, 100000, and 
150000 times. 
 
The EDS capability of TEM was used for elemental mapping of PLGA NPs produced by 
nanoprecipitation using both conventional and microfluidic method (Table 4.3). A single NP was 
focused, scanned and analyzed for its elemental composition. As expected, the results confirmed 
the presence of carbon and oxygen atoms in all formulations of NPs in similar levels, resulting from 
the presence of the polymer and the surfactant used in the production process.  Moreover, it was 
possible to detect sulfur, which is characteristic of DMSO, and fluorine, which is characteristic of 
EFV (Table 4.3). In relation to the sulfur element, a significant difference (*** p < 0.001) was 
observed between empty NPs produced by the two methods, demonstrating a higher content of 
DMSO within NPs produced by microfluidics, in comparison to the conventionally-produced ones. 
However, for the EFV-loaded NPs, no differences in the DMSO content were found between the two 
methods of fabrication. This can be attributed to the higher affinity of DMSO to the water presented 
in the continuous phase of the NPs compared to the EFV, leading to a competitive and faster 
diffusion of the solvent out of the NPs, while the drug was efficiently entrapped within the 
nanosystem. It is well-known that DMSO has an high hydrogen bonding affinity for water [245]. Still, 
the higher level of DMSO found in the empty NPs produced by microfluidics may raise some issues 
related to a possible organic solvent-associated toxicity, which, in turn, may hinder the progression 
of the formulations to a commercially available product. However, the following in vitro cell 
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viability tests will confirm if this level of solvent is biologically relevant to cause cytotoxicity. 
Moreover, as a possible solution to remove the solvent from the microfluidics-produced empty NPs, 
an extra step based on dialysis could be added in the end of the fabrication process [246]. In 
relation to the fluorine, a significant difference (* p < 0.01) was observed between EFV-loaded NPs 
produced by the two methods. The microfluidic method allowed the formation of NPs with 
detectable levels of fluorine approximately two times higher than the conventional method. This is 
in good accordance with the results obtained for the AE and DL of the formulations, revealing the 
successful association of EFV with NPs when using the microfluidic method of production.  
 
Table 4.3 – EDS analysis of PLGA NPs produced by nanoprecipitation using both conventional and microfluidic 
method. Results are presented as mean ± SD (n = 5). 
Element 
Associated 
substance 
NPs 
Average atomic (%) 
Type Method of production 
S DMSO 
Empty 
Conventional 0.02 ± 0.03  
Microfluidic 1.09 ± 0.10 *** 
EFV-loaded 
Conventional 0.04 ± 0.02 
Microfluidic 0.02 ± 0.03 
F EFV EFV-loaded 
Conventional 0.15 ± 0.10  
Microfluidic 0.37 ± 0.07 * 
 
S: sulfur; F: fluorine; DMSO: dimethyl sulfoxide; NP: nanoparticle; EFV: efavirenz. 
* p < 0.05; *** p < 0.001 (comparison done between the same NPs type inside each associated substance group). 
 
At this point of the work, NPs resulting from the nanoprecipitation technique performed by 
microfluidics using the co-flow geometry demonstrated to have a suitable profile to accomplish the 
purpose of this work in relation to physico-chemical characteristics. Thus, this formulation was the 
selected one to proceed with the next experiments.  
4.4 Microfluidic method: scaling experiment 
The aim of the scaling experiment was to understand the system behavior when the formulation 
final volume was decreased or increased ten times, and the scaling outcomes on NPs properties, 
regarding their Z-average, PDI, ζ-potential, AE and DL.  
Microfluidic methods are usually designed as systems which are easily adapted to allow different 
scalings while maintaining the same properties of the final product. On the first hand, scale-down is 
important to diminish the need for expensive and time consuming large scale studies. One the other 
hand, scale-up is important to achieve a high throughput of NPs production, and it is the first step 
into a potential industrial application.  
Therefore, the production of EFV-loaded NPs by microfluidics was run until a final volume of 
formulation of around 2 mL (scale-down) and 200 mL (scale-up). Then, these results were compared 
with the ones obtained for the 20 mL final volume (standard scale), already presented in the 
previous section. The results are shown in Table 4.4. 
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Table 4.4 – EFV-loaded NPs properties corresponding to the scale-down, standard scale, and scale-up. Results 
are presented as mean ± SD (n = 3).  
Method Z-average (nm) PDI ζ-Potential (mV) AE (%) DL (%) 
Scale-down 75.5 ± 2.2  0.087 ± 0.003 -13.0 ± 1.5 86.2 ± 7.6 11.5 ± 1.0 
Standard scale 72.8 ± 4.9 0.086 ± 0.004 -14.1 ± 1.3 80.7 ± 8.3 10.8 ± 1.1 
Scale-up 73.2 ± 8.0 0.080 ± 0.004 - 12.8 ± 1.8 87.6 ± 5.7 9.9 ± 0.5 
 
Z-average: average size; PDI: polydispersity index; ζ-Potential: zeta-potential; AE: association efficiency; DL: 
drug loading. 
 
No significant differences were found between formulations with different final volumes. Thus, 
the microfluidic system was able to form NPs with a consistent and reproducible structure, 
independently of the formulation volume. These findings proved the robustness of the microfluidic 
method, hence demonstrating the feasibility of the microfluidic chip to perform scaling experiments 
and produce batches of NPs with different volumes. Herein, the versatility of the microfluidic 
technology was proved.  
4.5 In vitro release test 
Previously to the release profile, the solubility of EFV in 0.2 % of poloxamer in PBS after 15 min 
and 24 h was determined to assure the presence of sink conditions. The value obtained for the 
solubility of EFV in this medium was 0.29 and 0.36 mg/mL for 15 min and 24 h, respectively. Herein, 
the addiction of a surfactant, poloxamer, to the PBS solution aimed to increase the solubility of the 
drug in the medium and to prevent a possible adsorption of EFV on the container surface [247]. 
Since EFV is a hydrophobic drug, the low values obtained for its solubility in the aqueous solution 
were expected [248].  
The release profile of EFV from PLGA NPs (Figure 4.9) was characterized by an initial rapid burst 
effect, with around 30 % of the drug being recovered from the medium in the first 30 min. An 
additional 20 % of EFV content was relatively slow released up to 9 h, and then the release ceased. 
This release behavior of drugs from PLGA NPs was frequently reported in the literature [249-252]. 
The mechanism responsible for the release of EFV from this DDS was a junction of the diffusion of 
the drug through the PLGA, and also polymer surface or bulk degradation, erosion, and swelling 
[253]. Moreover, it is known that the initial burst release is an outcome of the amount of drug which 
is near or attached to particles surface [254]. Oppositely, the amount of drug which is contained 
within the NPs core is usually released during a more prolonged period of time. The PLGA 
nanosystems are able to present this sustained release behavior since its internal structure is very 
well compacted, hence avoiding water penetration from the medium and promoting a relatively low 
drug diffusion out of NPs [255].  
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Figure 4.9 – In vitro release profile of EFV from microfluidics-produced PLGA NPs. 
4.6 Nanoparticles labeling  
Nanoparticles were labeled by 6-C encapsulation in order to further detect them during cellular 
assays. This encapsulation was done by microfluidics, using the model for the co-flow geometry, as 
described for EFV-loaded NPs.  
The 6-C was detected through fluorescence (ex. 460 nm, em. 510 nm). New calibration curves 
were set in the beginning of every experiment to verify the feasibility of the detection method. 
Firstly, a stock solution was prepared, containing 153 µg/mL of 6-C in DMSO and 0.1 % of TWEEN®-80 
in PBS (pH = 7.4), in a ratio of 1:12. Then, from the stock solution, a solution of 1 µg/mL of 6-C was 
prepared by dilution in 0.1 % of TWEEN®-80 in PBS (pH = 7.4). The standard solutions were prepared 
from this last solution by dilutions in the same medium. The calibration curve comprised a range of 
6-C concentrations from 0.002 μg/mL to 0.01 μg/mL, at equally spaced intervals. In Figure 4.10 is 
possible to find a model for this curve. The obtained calibration curves always presented a value of 
R2 between 0.990 and 0.999, which demonstrates the feasibility of the methodology [256]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 – Standard curve calibration for 6-C detection through fluorescence. 
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The Z-average, PDI, ζ-potential, and AE of 6-C loaded NPs are depicted in Table 4.5. As can be 
seen, the properties of 6-C loaded NPs were similar to EFV-loaded NPs resulting from the same 
methodology of production (Table 4.2), and thus fluorescent NPs were appropriate to mimic drug-
loaded NPs in cellular assays.  
 
Table 4.5 – 6-C loaded NPs properties. Results are presented as mean ± SD (n = 3).  
NPs type Z-average (nm) PDI ζ-Potential (mV) AE (%) 
6-C loaded  89.6 ± 5.5 0.106 ± 0.014 -12.8 ± 0.4 99.9 ± 0.0 
 
Z-average: average size; PDI: polydispersity index; ζ-Potential: zeta-potential; AE: association efficiency; NP: 
nanoparticle; 6-C: 6-coumarin. 
 
Previously to the release profile, the solubility of 6-C in 0.1 % of TWEEN®-80 in PBS after 24 h 
was determined to assure the presence of sink conditions. The value obtained for the solubility of 6-
C in this medium was 2.88 ng/mL. The results for the in vitro release of fluorescent NPs (Figure 
4.11) showed that after 24 h, only around 0.2 % of 6-C was released from PLGA NPs, which means 
that the fluorescence observed on cellular assays where the particles were used potentially 
corresponded to these nanosystem and not to free fluorescent dye [224]. Therefore, this system was 
approved to be used in some of the next experiments. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 – Release profile of 6-C from the nanosystem. 
4.7 Nanoparticles functionalization and characterization 
Nanoparticles were functionalized with a peptide-binding transferrin receptor in order to target 
the BBB, avoid drug-related side effects and enhance therapeutic efficacy. The structure of the 
peptide used in this process is shown in Figure 4.12.  
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Figure 4.12 – Structure of the 12-amino acids peptide used to functionalized the NPs [257]. 
 
The carbodiimide-derived EDC/NHS coupling chemistry was used to attach the peptide to the 
PLGA of NPs (Figure 4.13). Briefly, EDC reacted with the carboxyl groups (-COOH) of PLGA to form 
an active O-acylisourea intermediate, which consists on an unstable chemical. When in the presence 
of the stabilizer NHS, or its water-soluble analog (sulfo-NHS), EDC can couple this organic compound 
to the carboxyl groups of PLGA, hence establishing an NHS ester that is far more stable than the O-
acylisourea intermediate. Thus, the NHS ester was able to react with the amine groups (-NH2) of the 
peptide, forming a stable amide linkage between the peptide and PLGA [258].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 – EDC/NHS coupling chemistry. Adapted from [258]. 
 
Once the NPs are functionalized, they should be able to reach the brain, in the CNS, mainly by 
the transferrin receptor-mediated endocytosis pathway (Figure 4.14).  
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Figure 4.14 – Theoretical mechanism of the passage of functionalized NPs through BBB endothelial cells by the 
transferrin receptor. a) NPs functionalized with the 12-amino acids peptide should easily recognize the 
transferrin receptor of the BBB; b) transport of the endocytic vesicle containing NPs through the endothelial 
cells of the BBB; c) NPs reach the CNS; d) transferrin receptor is recycled back to the cell surface. Adapted 
from [259]. 
 
4.7.1 Average size, polydispersity index and surface charge  
After functionalization, NPs were evaluated for Z-average, PDI and ζ-potential. The results are 
shown in Table 4.6.  
 
Table 4.6 – Functionalized NPs properties. Results are presented as mean ± SD (n = 3).  
NPs type Z-average (nm) PDI ζ-Potential (mV) 
Functionalized empty  73.4 ± 1.7  0.155 ± 0.018 -15.4 ± 1.6 
Functionalized EFV-loaded  73.3 ± 1.7 0.177 ± 0.012 -16.3 ± 1.2 
Functionalized 6-C loaded  90.2 ± 2.0 0.186 ± 0.013 -13.0 ± 1.8 
 
Z-average: average size; PDI: polydispersity index; ζ-Potential: zeta-potential; EFV: efavirenz; 6-C: 6-coumarin. 
 
In comparison to the properties of the non-functionalized NPs (represented in Table 4.3 and 4.6 
for empty or EFV-loaded and 6-C NPs, respectively), only the PDI demonstrated statistically 
significant differences. However, previous studies already described the increase in PDI as an effect 
of the functionalization process [209, 224, 260]. Average size and surface charge did not change 
significantly.  
 
4.7.2 Bradford assay 
Bradford assay was used to indirectly quantify the amount of peptide associated with NPs by 
measuring the free peptide in the supernatant after each functionalization reaction.  
Simultaneously, standards with BSA and 12-amino acids peptide (used to functionalize the NPs) 
were prepared, and thus two calibration curves were obtained (Figure 4.15). The calculated protein 
concentration in the supernatants was 0 µg/mL using the data from both calibration curves, and 
therefore the calculated AE of the peptide to the NPs was 100 %. Still, these results should be 
carefully interpreted. On the first hand, since the amount of peptide added was very low in 
comparison to the amount of –COOH activated groups available, this value of AE of the peptide 
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could be acceptable due to the existence of spatial accessibility to occur the linkage between them. 
On the other hand, small peptides may present a lack of reactivy in the Bradford assay, and thus 
this method may not be the most sensitive one to detect them [261].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 – Peptide concentration measurement by Bradford Assay. a) Standard curve of BSA concentration 
versus absorbance at 595 nm; b) standard curve of 12-amino acids peptide concentration versus absorbance at 
595 nm. 
 
4.7.3 Nuclear magnetic resonance analysis   
Samples of commercial PLGA (used in the production process of NPs), functionalized and non-
functionalized empty PLGA NPs were dissolved in DMSO in order to verify the presence of their 
structural components by 1H NMR. 
The functionalized and non-functionalized PLGA NPs 1H-NMR spectra were compared with the 
spectra obtained from the commercial PLGA (Figure 4.16a). It was possible to observe that both 
nanoformulations presented characteristics peaks at 1.4 (3H), 4.8 (2H) and 5.2 (1H) ppm related to 
the -CH3, -CH2, and -CH protons of PLGA, respectively [262]. In addition, an intense peak related 
with TWEEN®-80 used in NPs preparation appeared at 3.6 ppm [263]. Since the amount of peptide 
used on functionalized samples was very small compared to the polymer, it was hard to obtain 
spectra with enough sensitivity to significantly detect peptide peaks on the samples functionalized – 
reason why detected differences were all small peaks. Besides that, a close observation of the 
functionalized PLGA NPs spectra (Figure 4.16b and 4.16c) allowed the confirmation of the presence 
of small peaks at -0.008 and -0.017 ppm which are described in the literature as traces of the 
presence of the peptide [224].  
 
Results and Discussion  55 
 
 
 
 
 
Figure 4.16 – 1H NMR analysis of samples. a) 1H NMR spectra (DMSO-d6) of commercial PLGA, functionalized and 
non-functionalized PLGA NPs at 400 MHz; b) spectra with magnification of functionalized PLGA NPs structural 
data; c) both nanoparticulate systems near to 0.00 ppm. Peak at 3.3 ppm is related with water presence in 
samples. 
 
Both Bradford and 1H NMR analysis resulted in outcomes which proved the presence of the 12-
amino acids peptide in functionalized PLGA NPs samples and the potential bioconjugation of this 
peptide to the nanosystem.  
4.8 Nanoparticles-associated metabolic viability assay 
In vitro cell viability determination after contact with NPs resulting from nanoprecipitation 
technique performed by microfluidics was assessed through a MTT assay in the hCMEC/D3 and 
ND7/23 cell lines (Figure 4.18a and 4.18b, respectively). The hCMEC/D3 cell line was chosen since 
brain endothelial cells represent the major cellular component of the BBB and the ND7/23 cells 
were used as a model of a sensorial neuron cell line of brain parenchyma.  
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4.8.1 ND7/23 cell line: assessment of the optimal cellular density  
In order to evaluate the best cellular density of the ND7/23 cell line for the MTT test, cells were 
seeded in concentrations of 0.001, 0.005, 0.010, 0.015, 0.020, 0.040, 0.060, 0.080, and 0.100  106 
cells/mL. Then, cells were incubated with supplemented DMEM during 24 h.  
After incubation with medium, the concentrations ranging from 0.040 to 0.100  106 cells/mL 
were immediately excluded, since they originated an excessive production of formazan crystals. The 
other concentrations were plotted in function of the average absorbance (Figure 4.17).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 – Plotting of cellular density per well versus average absorbance for the ND7/23 cell line.  
 
The best cell number for an MTT test should be the one which yields an average absorbance of 
the sample that mimics the PC between 0.75 and 1.25. Moreover and ideally, this number of cells 
should fall within the linear portion of the standard curve [264]. Therefore, the cellular density 
which fulfilled the requirements was 0.015  106 cells/mL.  
 
4.8.2 Nanoparticles safety evaluation  
A range of concentrations from 0.01 µM to 100 µM of free EFV, empty NPs, functionalized empty 
NPs, EFV-loaded NPs, and functionalized EFV-loaded NPs were tested on the hCMEC/D3 and ND7/23 
cell lines and then the metabolic activity was determined. As can be seen in Equation 3.4, the 
metabolic activity was estimated in comparison to the PC and NC for each group. 
In the context of the pre-clinical testing evaluation of the cytotoxicity of a medical device by in 
vitro techniques, the International Organization for Standardization (ISO) defined in the 10993-5 
norm that a material associated with a cell viability, directly correlated with cellular metabolic 
activity, equal or above 70 % is considered non-toxic [265]. In this work, metabolic activity of brain 
endothelial cells and neuron cells was found to be always above 90 % and 70 %, respectively, when 
in contact with all NPs at all evaluated concentrations. Therefore, NPs formulations should be 
considered non-toxic, and potentially safe. As expected, PC and NC for each group assumed 
metabolic activities of 100 and 0 %, respectively. 
For both cell lines, the cellular metabolic activity in the presence of free EFV concentrations of 
0.01 µM, 0.1 µM, 1 µM, and 10 µM did not present significant differences between them. For the 
hCMEC/D3 cell line, the highest concentration of free EFV (100 µM) was significantly different than 
the others (*** p < 0.001 for 0.01 µM; ** p < 0.01 for 0.1 µM; * p < 0.05 for 1 and 10 µM). In the case of 
the ND7/23 cell line, the free EFV concentration of 100 µM was also significantly different than the 
ones corresponding to 0.1 µM (** p < 0.01) and 0.01 µM (* p < 0.05). The concentration of 100 µM 
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demonstrated to cause severe damages to both cell types, resulting in the total absence of 
metabolic activity. According to the obtained results, the maximum concentration limit for the safe 
use of the free drug form in the hCMEC/D3 and ND7/23 cell line is probably defined between 10 µM 
- 100 µM, and 1 µM – 0.1 µM, respectively.  
Empty NPs concentrations did not present significant differences between them. The 
considerable cellular metabolic activity associated with this NPs group (> 90 %) for both cell types, 
which is similar to the PC, reinforces the apparent low contribution of NPs matrix to the emergence 
of loaded NPs cellular cytotoxicity phenomena.  
Functionalized empty NPs and functionalized EFV-loaded NPs demonstrated to have cytotoxic 
profiles similar to empty NPs and EFV-loaded NPs, respectively, indicating that the functionalization 
process with a peptide did not influence the safety of the nanosystems. 
Considering EFV-loaded NPs concentrations, no relevant differences were observed between 
0.01 and 100 µM in terms of cellular metabolic activity. However, a significant metabolic activity 
difference can be observed when comparing equal concentrations between this group and the free 
EFV one, except for the smaller and the two smaller concentrations for endothelial and neuron 
cells, respectively, as can be seen in Figure 4.18; this difference is particularly accentuated for the 
concentration of 100 µM (*** p < 0.001). The EFV-loaded NPs provided a higher cellular metabolic 
activity than the free drug, and, therefore, it is possible to state that the cellular cytotoxicity 
associated with free EFV can be diminished by encapsulating the drug in NPs, demonstrating that 
these nanocarriers have a protective role for EFV administration in the selected hCMEC/D3 and 
ND7/23 cell lines. Regarding the targeting ability of the nanosystems, to reach the same biological 
effect, it would be possible to use a lower therapeutic concentration of EFV in NPs compared to the 
free drug, and this can reduce EFV-associated side effects and unexpected adverse reactions; still, 
more detailed release kinetics studies are needed to corroborate this conclusion.  
In general, it was possible to denote that the neuron cell line was prone to present smaller 
values of cellular metabolic activity in comparison to the endothelial cell line. This may be mainly 
due to one of the principal EFV metabolites, namely, 8-hydroxy-efavirenz, which was already 
associated with cytotoxicity to neuron cultures [266]. Some mechanisms pointed out as capable of 
cause this neurotoxicity are modifications in the calcium homeostasis and cannabinoid system, 
stimulation of the release of brain pro-inflammatory cytokines, and mitochondrial damages. 
However, once again, this reduction in the cellular metabolic activity was attenuated by the 
encapsulation of EFV in NPs, which potentially minimized the toxic effect of the drug in the neuron 
cell line.  
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Figure 4.18 – Metabolic activity of hCMEC/D3 (a) and ND7/23 (b) cells when incubated with different 
concentrations of free EFV, empty NPs, functionalized empty NPs, EFV-loaded NPs, and functionalized EFV-
loaded NPs, during 24 h. (#) denotes a significant difference between free EFV 100 µM and the other 
concentrations in the same group, as described above. (*,**,***) denotes a significant difference (* p < 0.05, ** p 
< 0.01, and *** p < 0.001, respectively) when comparing equal concentrations between free EFV and EFV-loaded 
or functionalized EFV-loaded NPs group. 
4.9 Nanoparticles hemocompatibility assay 
The hemolysis test is useful to investigate the safety of parenteral-administered formulations, 
providing an estimation of the blood compatibility of materials. Erythrocytes are the most abundant 
cells in the bloodstream, and they may experience deformation or membrane damages derived from 
intravenous-administered pharmaceutical formulations [226]. Herein, the aim was to target NPs to 
the BBB after intravenous administration, in order to deliver EFV to the brain, in CNS. Thus, it is of 
extreme importance to test whether the NPs demonstrate hemolytic effect, and their behavior 
compared to the free drug, as well.  
Hemolysis is defined as the disruption or destruction of red blood cells, promoting the release of 
the iron-containing protein hemoglobin into the surrounding fluid. These cells may directly interact 
with biomaterials, or indirectly interact with their extracts [267]. In vivo, hemolysis is associated 
with pain during the release of hemoglobin, and pathological situations as anemia, vascular 
irritation, acute renal failure, or even death [268].  
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In this work, the free drug and all types of NPs formulations (empty, functionalized empty, EFV-
loaded, and functionalized EFV loaded) were directly incubated with erythrocytes in PBS in 
concentrations ranging from 0.005 µM to 50 µM. The results for hemolysis are shown in Figure 4.19. 
Besides the incubation with the free drug and NPs samples, the cells were also incubated with only 
PBS (NC) and 1 % of Triton X-100 in PBS (PC). 
 
 
 
 
 
 
 
 
 
 
Figure 4.19 – Percentage of hemolysis associated with the free drug, empty NPs, functionalized empty NPs, 
drug-loaded NPs, and functionalized drug-loaded NPs.  
 
As expected, the percentage of hemolysis calculated for the NC and PC was 0 % and 100 %, 
respectively. These percentages are correlated with samples hemoglobin concentration of 0.1 
mg/dL for the NC, and 209.5 mg/dL for the PC. The percentage of hemolysis for all samples at all 
analyzed concentrations was always below 2 % (hemoglobin concentrations between 2.1 and 3.7 
mg/dL) and no significant differences were found between the different groups. This means that 
neither the free drug, nor empty NPs, nor drug-loaded NPs can be considered dangerous for red 
blood cells. Herein, functionalized NPs demonstrated to have a hemolytic profile similar to the non-
functionalized NPs, and thus the functionalization process did not affect the hemocompatibility of 
the nanoformulations. The same was observed for the loaded NPs.  
The osmolarity of these formulations was also measured (considering that PBS and blood hold 
similar osmolarities), in order to understand the relation between their osmotic concentration and 
the osmotic concentration of blood. All formulations presented osmolarity values within the range 
for blood osmolarity, which is 285-300 mOsm/L [269], and thus osmolarity-related hemolysis was not 
expected to occur.  
In accordance to a guidance for in vitro hemolysis described by representatives of the Johnson & 
Johnson and Novartis Pharmaceuticals Corporation [268], hemolysis percentages below 10 % are 
related with nonhemolytic formulations, while hemolysis percentages above 25 % are related with 
hemolytic formulations. Thus, the nanosystems were considered nonhemolytic.  
Besides the quantitative test, the morphology of erythrocytes after interaction with NPs was 
also evaluated by SEM imaging (Figure 4.20). Since the quantitative test was not enough to conclude 
about the hemocompatibility of the formulations [226], this qualitative test worked as a proof of 
concept. Herein, only the maximum concentration of empty NPs and EFV-loaded NPs, 50 µM, was 
tested. The NPs demonstrated to have an impact on red blood cells similar to the NC and between 
them. So, no considerable morphological changes in the cells were observed.  
All these findings supported the theory that the NPs formulations are hemocompatible, and 
therefore could be safe for intravenous administration.  
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Figure 4.20 – SEM images of red blood cells morphology after interaction with PBS (NC), and 50 µM of empty 
NPs and EFV-loaded NPs in PBS, during 3 h. From left to right, each column of images corresponds to a 
different magnification, namely, 1000, 5000, 10000, and 15500 times. No relevant morphological differences 
were found between the three groups.  
4.10 Evaluation of cell-nanoparticle interaction 
The interaction between non-functionalized and functionalized NPs with human BBB endothelial 
cells was quantitatively studied over time through flow cytometry.  
Figure 4.21 demonstrates the gating strategy adopted to perform the analysis. On the left panel 
is possible to observe the viable cell population on a forward scatter area (FSC-A) vs. sideward 
scatter area (SSC-A) dot plot. On the right panel doublets and aggregates were identified, and 
excluded, and is possible to observe the gated cells on a FSC-A vs. forward scatter height (FSC-H) 
dot plot.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 – Gating strategy applied in FACS analysis. 
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The results for the mean fluorescence intensity (MFI) for both groups and time points (Figure 
4.22) demonstrated the absence of significant differences between non-functionalized and 
functionalized NPs in respect to their interaction with BBB endothelial cells. However, it was 
possible to notice a trend in the MFI evolution, with higher values attributed to the functionalized 
NPs. This data suggested that the functionalization process applied was not sufficiently effective. 
Besides the presence of the peptide associated with the NPs, as proved by the previously mentioned 
Bradford test and 1H NMR spectroscopic analysis, this type of functionalization was not site-
oriented. Thus, there were different possibilities for the linkage due to the existence of several 
carboxyl and amine groups at the PLGA and peptide, respectively [224]. This may affect the 
structural and spatial availability of the peptide for the binding process to the transferrin receptor, 
hence avoiding the increase in cells-NPs interaction. Moreover, since the 12-amino acids peptide 
presented positive charge at the pH in which the functionalization process was carried out 
(isoelectric point of the peptide around 10.5; functionalization process occurred at pH = 5.5) and 
the surface charge of NPs was negative (ζ-potential around -14 mV), the peptide may not be 
covalently linked to NPs, but only adsorbed to the surface based on electrostatic interactions. This 
justifies the results obtained for Bradford test and 1H NMR spectroscopic analysis, which confirmed 
the presence of the peptide.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22 – MFI results for non-functionalized and functionalized NPs after 1 h and 3 h of incubation with 
human BBB endothelial cells. 
 
Still, an attempt based on a site-specific immobilization of the peptide on NPs surface could be 
introduced in the methodology to improve the efficacy of the functionalization process. Herein, it 
would be reasonable to use a peptide with only one amino group available to bind the PLGA of the 
NPs. Thus, the remaining amino groups of the peptide would be available to bind the transferrin 
receptor. 
4.11 Permeability study 
Simultaneously to the evaluation of cell-nanoparticle interaction, a permeability assay was 
conducted through a cell-based BBB in vitro model based on a monolayer of hCMEC/D3 cells 
previously developed [227, 228]. This model demonstrated to be suitable to predict drug passage 
across the BBB. The monolayer grew in a Transwell® system using cell culture inserts, containing a 
permeable membrane on the bottom. The test samples were added to the apical compartment, and 
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the amount of drug that was able to permeate through the insert membrane was detected on the 
medium of the basolateral compartment. The scheme of this setup is demonstrated in Figure 4.23.  
 
 
 
 
 
 
 
 
 
Figure 4.23 – Scheme of the cell-based BBB in vitro model used to perform the permeability study.  
 
The TEER is often used as a measure of the tightness and integrity of cell monolayers. It is 
considered the measurement of the resistance of the monolayer in relation to the flow of charged 
ions through it. The increase in TEER values is associated with more energy spent to move an ion 
across the cell layer, and is accepted as an indication of the closing of the tight junctions located 
between cells [270-272]. During the 8 days needed to develop the BBB in vitro model, TEER was 
monitored. As expected, and due to cells replication, a gradual increase in TEER values was 
observed (Figure 4.24). In the end, TEER value was within the range 40-70 Ω.cm2, which is 
acceptable for this type of BBB in vitro models consisting on a hCMEC/D3 cell monolayer [273, 274].  
 
 
 
Figure 4.24 – Evolution of TEER during the 8 days necessary to develop the BBB in vitro model. 
 
Confocal microscopy was used to evaluate the morphological characteristics of BBB endothelial 
cells of the monolayer at the day 8 of the in vitro model. Moreover, microscopy data was useful to 
understand whether the model was indeed constituted by a cellular monolayer, or a superposition 
of layers. Images are represented in Figure 4.25.  
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Figure 4.25 – Evaluation of the BBB in vitro model integrity by confocal microscopy. DAPI and Alexa Fluor® 594 
WGA were used to stain cellular nuclei in blue (left panel) and membranes in red (middle panel), respectively. 
Then, the images were superposed (right panel). Scale bars of 50 μm were represented. 
 
It was concluded that, in fact, the BBB in vitro model consisted on a monolayer of hCMEC/D3 
cells. It was possible to observe cells with a prolonged morphology and growing in a parallel 
direction, resulting in a confluent membrane. 
When the BBB was established (8th day), EFV permeability was determined either as a free drug 
or loaded in both non-functionalized and functionalized NPs, in order to understand to what extent 
these nanosystems could enhance the bioavailability of EFV across this biological barrier. Moreover, 
it is important to mention that this assay was conducted simultaneously to the evaluation of cell-
nanoparticle interaction, and thus the outcomes of that experiment were not known before start 
this permeability study. The results were expressed in percentage of permeability (Figure 4.26) and 
Papp (Figure 4.27). The TEER values monitored during the permeability assay (Figure 4.26), showed 
no significant deviations from the range 40-70 Ω.cm2, which proved the membrane integrity and the 
reliability of the model to proceed with this experiment. In relation to the results, no significant 
differences were observed for percentage of permeability and Papp of free EFV, non-functionalized 
EFV-loaded NPs, and functionalized EFV-loaded NPs. The amount of drug detected in the apical 
compartment and cell lysates after the assay were very similar for all samples, as well. This was in 
accordance with the outcomes of the evaluation of cell-nanoparticle interaction, whose data 
suggested that the functionalization process applied to EFV-loaded NPs was not sufficiently 
effective. However, once again, it was possible to notice a general trend in the permeability across 
the BBB model consisting on functionalized EFV NPs > non-functionalized EFV NPS > free EFV.  
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Figure 4.26 – TEER and percentage of EFV permeability evolution during the permeability study.  
 
As mentioned in the previous section, a possible solution to increase the permeability of EFV NPs 
would involve a site-oriented functionalization of the nanoparticulate systems with a transferrin 
receptor-binding peptide. When an effective functionalization is achieved, an improved interaction 
between NPs and BBB endothelial cells is expected, as well as an increase in NPs permeability 
across endothelial cells monolayer [224, 228].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27 – Papp results for the EFV permeability study. 
 
Finally, it is important to mention that, although the results for the functionalized NPs 
interaction and permeability across BBB endothelial cells were less positive and even unexpected, 
these two studies were crucial to understand in which aspects is necessary to improve the 
nanosystem. Only in this way it is possible to reach a final formulation with suitable properties to 
move forward to a potential commercial application.  
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Chapter 5 
Conclusion 
5.1 Work conclusions 
In the present work, EFV-loaded PLGA NPs were developed using the nanoprecipitation 
technique. This technique was performed by the conventional methodology, including the regular 
procedure and a modified version, and microfluidics, using the co-flow and flow-focusing 
geometries. A dispersed phase, containing PLGA and EFV dissolved in DMSO, and a continuous phase, 
containing a solution of TWEEN®-80, were used. Additionally, an optimization of the flow rates of 
the two phases inside the microfluidic chip was conducted, in order to find the best arrangement in 
terms of NPs final properties. 
The physico-chemical properties of NPs obtained for the microfluidic method were compared 
with the ones obtained for the conventional process. According to the obtained results, performing 
the nanoprecipitation technique by microfluidics using the co-flow geometry was indeed 
advantageous. The obtained particles presented a smaller size compared to the ones formed by the 
conventional method (around 70 nm), comparable features to the conventional procedure regarding 
PDI (around 0.1), and less negative surface charge (around -14 mV). Furthermore, EFV-loaded NPs 
resulting from microfluidics-assisted nanoprecipitation technique demonstrated a remarkable 
increase in AE (around 80 %) and DL (around 10 %) compared to the conventionally-performed 
method, which are key aspects to achieve the desired drug delivery nanosystem therapeutic effect. 
Morphological analysis proved the round-shaped profile of the NPs, and chemical screening 
reinforced the increase in the amount of EFV associated to the NPs when they are produced by 
microfluidics, as well as the residual quantity of DMSO presented in the nanoformulation. Moreover, 
the in vitro release assay demonstrated that these PLGA NPs produced through microfluidics were 
able to exhibit a sustained release of EFV over time from their matrix.  
By performing a scaling experiment of ten times regarding the final volume of NPs batch, the 
robustness of the microfluidic method was successfully demonstrated. It was possible to decrease 
and increase ten times the final volume of NPs batch without observing changes in the final 
properties of particles. This was a great achievement, especially for the scale-up assay, since it 
symbolized a preliminary step towards the application of the microfluidic technology to produce 
drug-loaded NPs in industrial dimensions. Besides the formulation parameters, it is important to 
66  Conclusion 
 
state the inherent advantages of microfluidics in comparison to the conventional methodology. The 
microfluidic method is far more fast, user-friendly and easy to handle. 
The nanosystem resulting from the nanoprecipitation technique executed by microfluidics using 
the co-flow geometry was tested in in vitro cellular assays. The NPs proved to be safe to be used 
with brain endothelial cells (hCMEC/D3 cell line), the major BBB cellular component, and neuron 
cells (ND7/23 cell line), a cellular population representative of the brain parenchyma environment. 
Herein, the effectiveness of the nanoparticulate system to avoid cytotoxicity in relation to the free 
drug was proved. Moreover, NPs proved to be nonhemolytic, demonstrating an associated 
percentage of hemolysis of only around 1-2 % and absence of changes in the normal morphology of 
red blood cells. This was important to support the intravenous administration of the nanosystem. 
Then, NPs were functionalized with a transferrin receptor-binding peptide using the 
carbodiimide coupling chemistry. Since this receptor is overexpressed at the BBB, the 
functionalization strategy was expected to be associated with an increase in the interaction of NPs 
with BBB endothelial cells (hCMEC/D3 cell line), and a consequent increase in the permeability of 
the nanosystem through this biological barrier. For the permeability study, the integrity and 
presence of a monolayer in the BBB in vitro model used, was confirmed. For both cells-NPs and 
permeability studies, no significant differences were observed between non-functionalized and 
functionalized NPs. However, it was possible to observe a trend, since higher values of interaction 
and permeability through hCMEC/D3 cells were attributed to the functionalized NPs. This 
demonstrated that, besides the proved bioconjugation of the peptide to the NPs, the non-oriented 
functionalization was not a good strategy to be adopted, since it may affect the spatial 
bioavailability of the peptide to bind to the transferrin receptor.  
In conclusion, and attending the results obtained so far, the work inherent to this dissertation 
allowed the successful microfluidics-based development of a PLGA nanosystem with suitable 
properties to encapsulate EFV and to be possibly administered by the intravenous route, in order to 
target the BBB. This technology proved to bring advantages in the loading of this ARV drug in NPs 
with tunable and favorable biological properties.  
5.2 Future work  
Besides all the work performed in the scope of this dissertation, there is always room for 
improvement and different attempts could be introduced to improve the nanosystem under 
development. 
First and foremost, the issue related to the functionalization process of NPs and, consequently, 
its permeability trough the BBB in vitro model, is prone to be improved. Herein, a site-oriented 
functionalization would be a priority. It could be possible to use a peptide with the above 
mentioned structure but adding an extra cysteine on the carboxyl termination, whose sulfhydryl 
group would be the only connection point with the carboxyl groups of the PLGA, by using a specific 
linker. In this way, the remaining amino acids of the peptide would be available to bind the 
transferrin receptor. Another alternative would be to use the initial peptide but somehow blocked 
in order to have only one amine group available to react with the PLGA.    
The nanoparticulate system developed by microfluidics could also be evaluated for its antiviral 
activity, comparing the efficiency of the EFV-loaded NPs and the free EFV in the interference with 
HIV replication in the viral reservoir in study, the brain.  
Another alternative would be to study the versatility and scaling opportunity of the microfluidic 
method, by encapsulating other ARV model drugs. Besides this, the microfluidic method could be 
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used to produce nanosystems encapsulating drugs used in the therapy of other pathologies, such as 
anticancer drugs. Moreover, it would be important to test the behavior of the system during the 
production of nanosystems with different polymeric matrices, as well as the final properties of the 
obtained NPs. The production of NPs with a skeleton based on a diblock copolymer of PLGA and 
polyethylene glycol would be a good attempt, emphasizing the benefits of polyethylene glycol in a 
possible intravenous administration. In relation to this, besides the evaluation of NPs 
hemocompatibility, it would be important to perform other safety studies. Herein, it would be 
pertinent to accomplish protein adsorption, coagulation, and activation of the complement system 
studies.  
Regarding the microfluidic chip, the production of NPs using a different platform, or even a 
microfluidizer, could be tried. Moreover, the manufacturing of PLGA NPs to encapsulate EFV using 
droplet microfluidics, based on emulsion techniques, could be explored.  
Finally, the in vivo study for the assessment of biodistribution, safety and therapeutic efficiency 
of the nanosystem developed by the microfluidic tool would be essential to prosecute for a clinical 
application of the product. 
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